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Abstract 
 
During the progression of prostate cancer, the adhesion molecule 
epithelial (E)-cadherin can be lost from the cell surface by ADAM15 proteolytic 
processing, generating an extracellular 80kDa fragment referred to as soluble E-
cadherin (sE-cad). Contrary to observations in cancer, the generation of sE-cad 
appears to correlate with ADAM10 activity in benign prostatic epithelium. The 
ADAM10-specific inhibitors INCB008765 and proA10 inhibit sE-cad generation, 
downstream signaling, and cell proliferation. Addition of EGF or amphiregulin to 
benign prostatic hyperplasia cells (BPH-1) or immortalized prostate epithelial 
cells (PrEC) increases the amount of sE-cad shed into the conditioned media 
and bound to EGFR. EGF-associated shedding appears to be mediated by 
ADAM10 as shRNA knockdown of ADAM10 results in reduced sE-cad 
generation.  
To examine the physiologic consequence of sE-cad on prostatic 
epithelium, we treated cells with a sE-cad analog (Fc-Ecad), which resulted in 
phosphorylation of EGFR, signaling through ERK, and cell proliferation. Pre-
treating cells with cetuximab, a therapeutic antibody against EGFR, decreased 
the ability of Fc-Ecad to induce EGFR phosphorylation, downstream signaling 
and proliferation. These data demonstrate that ADAM10-generated sE-cad may 
have a role in EGFR signaling independent of traditional EGFR ligands.  
ix 
 
In order to better characterize the role of ADAM10 in normal prostate 
biology, we generated prostate specific knockout mice utilizing probasin (Pb) 
driven Cre. Preliminary analysis of Adam10 loxP/loxP Pb-Cre mice indicates an 
unexpected epithelial hyperplasia into the luminal space and areas of continued 
ADAM10 expression. However, cell lines generated from Adam10 loxP/loxP Pb-Cre 
mouse prostates express no ADAM10.  
Because of our interest in targeting ADAM15 in prostate cancer, we 
initiated studies investigating potential inhibitors and domain requirements for E-
cadherin cleavage. In these preliminary studies, the EGF-like domain of ADAM15 
appears to be critical for sE-cad generation. We have also observed that the 
ADAM10 inhibitor, INCB08765, can inhibit ADAM15 activity during in vitro and 
CD23 peptide cleavage assays. Furthermore, ADAM15 and ADAM10 co-
immunoprecipitate as a catalytically active unit. These studies suggest a novel 
role for the EGF-like domain of ADAM15 and present an interesting observation 
of functional interaction between ADAM10 and ADAM15.  
1 
 
Chapter 1: Introduction 
 
Benign and malignant prostatic disease 
 The human prostate is a walnut sized organ, which sits at the base of 
bladder and surrounds the urethra. The gland is comprised of epithelial cell acini 
which are separated by fibromuscular stroma (1). Each acinus is comprised of 
secretory luminal cells, surrounded by basal cells and the basement membrane.  
The two most common diseases of the prostate gland are benign prostatic 
hyperplasia (BPH) and prostate cancer.  
 BPH is characterized by lower urinary tract symptoms (LUTS), which 
manifest as difficult and painful voiding (1). The causes of BPH remain poorly 
characterized, although androgen receptor (AR) and epithelial-stromal 
interactions appear to play a critical role in disease pathology (2, 3). Alpha 
blockers, which target alpha1 adrenergic receptors on smooth muscle cells, 
inhibit contraction of the fibromuscular stroma, and provide symptom relief but no 
reduction in prostate volume; conversely, 5-alpha-reductase inhibitors target the 
conversion step of testosterone to dihydrotestosterone (DHT), resulting in low 
tissue levels of DHT, inducing prostate epithelial cell death and reductions in 
prostate volume (2).  
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Unlike BPH, which is characterized as a benign disorder and limited to the 
prostate gland, prostate cancer is capable of migrating through the prostatic 
capsule and metastasizing to distant sites. Because prostate cancer retains AR, 
and is initially dependent on AR signaling, AR ablation therapy is the first line of 
treatment for metastatic disease. While successful for a time, eventually the 
majority of metastatic prostate cancer patients will relapse and develop castration 
resistant prostate cancer (CRPC) (4). Although CRPC is no longer sensitive to 
androgen ablation therapy, AR signaling continues through a variety of 
mechanisms including increased AR expression, splice variants, ligand-
independent activation, and increased androgen and DHT synthesis from weak 
adrenal androgens (5). Because CRPC is no longer sensitive to androgen 
ablation therapy, but still dependent on AR signaling, efforts continue to 
therapeutically target the AR pathway. For example, abiraterone treatment 
targets CYP17A1, which contributes to the turnover of adrenal androgens to DHT 
(6). Conversely, other researchers are focusing on alternative pathways which 
may drive CRPC.   
 
Epidermal growth factor receptor family 
The epidermal growth factor receptor (EGFR) family is an emerging area 
of CRPC research and targeted therapy. The EGFR family is comprised of four 
transmembrane tyrosine kinase members: EGFR (ErbB1, HER1), HER2 (ErbB2, 
Neu), HER3 (ErbB3), and HER4 (ErbB4) (7). The EGFR family members contain 
a cysteine-rich ligand binding domain, a transmembrane domain, and a 
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cytoplasmic tyrosine kinase domain. Signaling is achieved by an EGF-like ligand 
binding to a single receptor, which can then homo- or hetero-dimerize with an 
adjacent EGF-like ligand bound receptor via a “dimerization loop” generating the 
functional complex (8). Complex formation allows for transautophosphorylation of 
the kinase domain, which allows for the docking of Src homology (SH2) domain 
or phosphotyrosine binding (PTB) containing proteins, such as Src, Grb2, and 
phosphoinositol 3-kinase, which mediate further downstream signaling events 
(9).  
The binding affinities of ligand to receptor depend on the receptors 
existing as dimers. EGFR binds EGF, transforming growth factor alpha 
(TGFalpha), amphiregulin (AREG), epiregulin (EPR), betacellulin (BTC), heparin 
binding EGF (HB-EGF), and biregulin (BiR), an engineered chimera of EGF and 
heregulin (HRG) (10). HER2 has no reported direct ligand, but its active 
conformation (11) allows it to be a preferred heterodimerization partner with other 
EGFR family members (12). Conversely, HER3 can bind HRGbeta, HRGalpha, 
and BiR (10), but has a catalytically dead kinase domain, so it must 
heterodimerize with EGFR, HER2, or HER4 in order to transduce signals (13).  
Interacting with HER2 allows HER3 to also bind neuregulin-2beta (NRG2beta) 
and EPR (10). HER4 binds BTC, HRGbeta, BiR, NRG2beta, HRGalpha, NRG3, 
but in association with HER2, it can also bind EGF, EPR, HB-EGF, and 
TGFalpha (10). The ability of each heterodimer to bind different ligands results in 
signaling diversity, which has implications in development and disease (7).  
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In the normal adult prostate, EGFR is expressed in basal cells and is 
localized in the lateral membrane junctions between the basal and luminal 
epithelium, while in BPH patients, EGFR staining expands to include moderate 
staining in a portion of luminal epithelium (14). 36% of BPH samples over-
express EGFR (1.7-9.0 fold over controls) and 63% over-express HER2 (15), 
with increasing levels of EGFR expression correlating with BPH grade (16). 
Some studies have even reported that by immunohistochemistry, BPH samples 
express more EGFR than prostate cancer samples (14, 17). These results 
suggest that EGFR may be a component of a regulatory pathway involved in 
epithelial hyperproliferation in the prostate gland (18) and a potential target for 
therapy.  
In prostate cancer, expression of EGFR, HER2, and HER3 correlates with 
more advanced disease and poor clinical outcome. EGFR staining is strongly 
associated with CRPC and EGFR family member signaling may contribute to 
androgen independence (19). Whether this is due to the suppression of AR by 
EGFR and HER2 signaling (20) or the failure of androgens to suppress EGFR 
expression in prostate cancer (21) remains to be determined. HER2 expression 
in prostate cancer has been associated with androgen-independent AR signaling, 
poor survival in CRPC, and may promote prostate cancer cell growth in bone 
(22-24). HER3 is also over-expressed in prostate cancer, has been observed in 
the nuclei of sections and cell lines, and high expression correlates with poor 
clinical outcome (25). Unlike the other family members, HER4 expression is a 
positive prognostic marker for hormone-sensitive tumors (23). These data 
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suggest that some EGFR family members support CRPC and patients could 
benefit from direct targeting of EGFR family members or metalloproteases, such 
as the ADAM family, which promote EGFR family signaling.  
 
A disintegrin and metalloprotease (ADAM) family 
ADAM10 and ADAM15 are members of the disintegrin family of zinc-
dependent metalloproteases which, in humans, is composed of 25 members, of 
which 13 members (including ADAM10 and 15) are catalytically active (26). 
Family members are characterized by five extracellular domains: prodomain, 
metalloprotease, disintegrin, cysteine-rich, and EGF-like. The multiple domains of 
ADAMs allow for a myriad of functions including proteolysis, integrin binding, and 
signal transduction (26). ADAM10 is predominantly a sheddase, which is known 
to cleave EGF-like ligands from the cell-surface, thus promoting EGFR family 
member signaling (27). ADAM10 also plays a critical role in the regulated 
intramembrane proteolysis (RIP) of Notch, CD44, and Fas ligand, whereby 
sequential processing of the pro-form of the protein by ADAM10 then gamma-
secretase complex allows the intramembrane fragment to enter the nucleus, bind 
DNA, and induce transcription of target genes (28). The catalytic domain of 
ADAM10, therefore, plays a critical role in cellular signaling.  
The cytoplasmic domain of ADAM10 is predominantly a regulatory 
component, with a proline-rich portion being required for correct baso-lateral 
localization of ADAM10 to the membrane (29). This process may be mediated by 
Src homology 3 (SH3) domain containing proteins, such as Lck, MAD2, SAP97, 
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Eve-1, and PACSIN3 which bind the ADAM10 cytoplasmic tail PXXP motif (26). 
Additionally, the catalytic activity of ADAMs can be controlled by the 
phosphorylation status of the cytoplasmic tail. In the prostate, the G-protein 
coupled receptor (GPCR) CXCR4 can respond to the chemokine CXCL12 by 
activating Src, which can in turn activate ADAM10, thus mediating amphiregulin 
shedding and EGFR signaling (30).  
Frequent disregulation of ADAM10 in inflammation and disease has made 
the protein’s catalytic domain a target for therapy (31-35). In the prostate, 
membranous ADAM10 expression is high in BPH patient samples, while prostate 
cancer patients lose membranous expression and gain nuclear staining of an 
ADAM10 cytoplasmic domain fragment (36). In vitro, the ability of the ADAM10 
cytoplasmic domain to translocate into the nucleus is dependent upon DHT, 
which allows AR to bind processed ADAM10 and translocate into the nucleus 
(36). Interestingly, DHT treatment of these cells also increases ADAM10 
expression (37). The nuclear translocation of ADAM10 requires that it undergo 
RIP, which has been reported to be mediated by ADAM9 and 15, as well as 
gamma-secretase (38). These data suggest that while ADAM10 may play a role 
in benign proliferative disorders, its catalytic activity on the cell surface will likely 
be diminished in diseases where ADAM15 is over-expressed and shedding 
ADAM10 from the cell surface. It is worthy of note that this cleaved soluble 
ADAM10 retains its catalytic activity to some degree (38), an observation that 
may have clinical implications and warrants further investigation.  
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The expression of ADAM15 is widespread in  human tissues, but it is the 
highest in mesenchymal stem cells and the urogenital system (26). It is also 
significantly over-expressed in breast, prostate, ovarian, gastric, and lung cancer 
(39). Unlike ADAM10, ADAM15 only has five reported substrates: CD23, pro-
amphiregulin, pro-HB-EGF, and E- and N-cadherin (40-44), but its unique RGD 
sequence in the disintegrin domain, also allows interactions with alphavbeta3, 
alpha5beta1, and alpha9beta1 integrins (45-47). Interestingly, while alphavbeta3 
and alpha5beta1 integrins require the RGD sequence for ADAM15-integrin 
binding (45, 46), alpha9beta1 binding occurs independently of this motif (47). The 
extracellular domain of ADAM15, therefore, can serve as an adhesive or catalytic 
unit, depending on the circumstance.  
The cytoplasmic tail of ADAM15 can associate with the Src family tyrosine 
kinases Lck, Hck, Abl, and Src, as well as MAD2, Grb2 (48). While the 
associations between Lck and Hck are potentiated by ADAM15 cytoplasmic tail 
phosphorylation, both kinases are able to phosphorylate the tyrosine residues of 
ADAM15 themselves (48). Splice variants of ADAM15 occurring in the 
cytoplasmic tail have varying affinities for Hck and Lck (49), which may have 
clinical implications in breast cancer, where certain splice variants correlate with 
dramatic decreases in patient survival (50). In vitro, these splice variants alter cell 
adhesion, motility, migration and association with intracellular effectors such as 
Src (50) which mediates the catalytic activity of ADAM15 (51). The association 
between the cytoplasmic tail of ADAM15 and the Src family members suggest 
that these interactions may mediate proteolysis and have implications in 
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adhesion, migration, and disease progression (48, 50, 51). ADAM15 has also 
been shown to be an effecter of GPCR signaling whereby it responds to 
lysophosphatidic acid (LPA) and promotes EGFR signaling (42).   
In the prostate, ADAM15 expression is much higher in localized and 
metastatic cancer than in BPH or normal tissue (39), and our previous studies 
have implicated ADAM15 in the malignant progression of breast and prostate 
cancer (43, 44). The catalytic and disintegrin activity of ADAM15 has also been 
reported to mediate inflammation (52, 53) and platelet aggregation (54).  The 
ability ofADAM15 to promote tumor growth and support metastasis in prostate 
cancer (43), makes ADAM15 a therapeutic target of interest.  
Unlike the Adam10 -/-  mouse which is embryonic lethal at embryonic day 
9.5, with defective central nervous system and heart developments (55), the 
Adam15 -/- mouse is viable, demonstrating that ADAM15 does not play a critical 
role in development (56).  Studies of tissue specific Adam10-/-  mice have also 
indicated a critical role for ADAM10 in brain, cardiovascular, thymocyte, skin, and 
marginal zone B cell development (57-61), suggesting ADAM10 may also play 
critical roles in adult tissues. Conversely, studies of adult Adam15-/- mice have 
indicated that ADAM15 plays homeostatic roles in cartilage and bone (62, 63), 
and only under pathological conditions such as hypoxia-induced proliferative 
retinopathy or implantation of melanoma xenografts do Adam15-/- mice exhibit 
defects in angiogenesis and tumor growth (56). These studies suggest that 
targeting ADAM15 in cancer would most likely produce limited side effects to the 
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patient, as compared to targeting ADAM10 which appears to play a critical and 
active role in adult tissues.  
 
Epithelial (E) -cadherin 
E-cadherin is a homophilic, calcium-dependent, adhesion protein, which is 
expressed at adherens junctions between epithelial cells.  E-cadherin has an 
extracellular region comprised of five domain repeats, each one containing a set 
of seven beta-sheets arranged in an immunoglobulin fold (64). Adhesion is 
achieved by lateral dimerization between E-cadherin molecules on the same cell, 
creating a homodimer which can then interact with an adjacent E-cadherin 
homodimer on a neighboring cell via cadherin repeat 1 (EC1) (65).  
Although E-cadherin is predominantly a homophilic adhesion molecule, it 
also exhibits heterophilic interactions. Of particular interest, E-cadherin can 
associate with CD103, killer cell lectin receptor G1 (KLRG1), and EGFR (66-68). 
The E-cadherin receptor, CD103 or alphaEbeta7 integrin, is located on T 
lymphocytes and helps to target T cells to epithelial cells, where it binds extra 
cellular domains EC1 and EC2 of E-cadherin (66).  Another receptor for E-
cadherin, KLRG1, is expressed on T cells and natural killer (NK) cells, where the 
binding of KLRG1 to E-cadherin-expressing cells prevents the lysis of epithelial 
targets (68) and is responsible for controlling the activation threshold of NK and T 
cells and thereby suppressing immune response (69).   
E-cadherin can also interact with receptor tyrosine kinases, such as 
EGFR. E-cadherin interaction with EGFR is dependent upon the extracellular 
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domain of E-cadherin and independent of beta-catenin and p120 binding (70). 
Moreover, the re-expression of E-cadherin in deficient cell lines inhibits ligand-
dependent activation of EGFR (70).  Work in diffuse gastric type carcinoma with 
an E-cadherin mutant lacking exon 8, which lies in the extracellular domain, 
demonstrated that mutant E-cadherin bound EGFR less efficiently and this 
retarded EGFR internalization in response to EGF (71). The association of EGFR 
with E-cadherin, therefore, can provide an inhibitory signal for EGFR.  
Within the cell, E-cadherin interactions support adhesion established 
through homodimerization. The cytoplasmic tail of E-cadherin associates directly 
with beta-catenin, p120, and indirectly with alpha-catenin.  Beta-catenin binding 
to E-cadherin provides structural support and aids in transport of E-cadherin to 
the baso-lateral plasma membrane (72). The formation of this ordered structure 
allows for binding of alpha-catenin, which can bind actin, stabilizing and 
coordinating actin dynamics at the adherens junction (73, 74). p120 binding to E-
cadherin also stabilizes the complex and maintains high E-cadherin levels (75).  
Regulation of E-cadherin adhesion can occur by altering the composition of the 
cadherin-catenin complex, the presence growth factors, tyrosine phosphorylation 
of the cadherin-catenin complex, p120 binding to E-cadherin, and the activity of 
small GTPases and proteins which aid in cell polarity determination (76), as well 
as cleavage in the extracellular or cytosolic domains.   
The disruption of E-cadherin function by proteolytic cleavage can occur in 
the extracellular domain or cytosolic tail of E-cadherin. The initial observation of 
E-cadherin cleavage was reported by Wheelock et al who observed an 80kDa 
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soluble E-cadherin in the conditioned media of MCF-7 breast cancer cells (77). 
This fragment, containing the five extracellular domains of E-cadherin and 
referred to as sE-cad, could disrupt adherens junctions of mouse mammary 
tumor cells (77). To date, members of the A Disintegrin and Metalloprotease 
(ADAM) family (ADAM10 and 15), matrix metalloprotease (MMP) family (MMP-2, 
3, 7, 9, and 14), Kallikrein-7, and plasmin have all been implicated in the 
generation of sE-cad (44, 78-92).  
Previous studies in our laboratory have focused on ADAM15 dependent 
cleavage of E-cadherin to sE-cad. Initial studies by Kuefer et al identified 
ADAM15 as the most highly over-expressed protease in prostate cancer 
progression (39) and later studies demonstrated that ADAM15 was critical for 
tumor maintenance, cancer cell-endothelial cell interaction, and metastasis (43). 
Najy et al also demonstrated that serum withdrawal from breast cancer cells 
induced E-cadherin cleavage by ADAM15, and the generation of sE-cad could be 
abrogated by shRNA knockdown of ADAM15 or increased by ADAM15 over-
expression (44). Our unpublished observations suggest this is also the case in 
prostate cancer cells.  
The observation that ADAM15 is not highly expressed in BPH (93) and our 
early studies suggested that in normal prostate biology ADAM10 is a more likely 
E-cadherin sheddase. E-cadherin and ADAM10 co-localize at the adherens 
junction (29), and ADAM10 has been implicated in E-cadherin cleavage in 
keratinocytes and gastric cancer cell lines (83, 84). Moreover, the high 
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membranous expression pattern of ADAM10 in BPH patients (36), suggests it 
might play a role in normal or proliferative disorder prostate biology.   
The presence of sE-cad in patient fluids is a negative prognostic factor in 
multiple disease states (reviewed in Chapter 2). The loss of E-cadherin by 
promoter hypermethylation, gene deletion or mutation (94) and proteolytic 
cleavage (77), results in the liberation of beta-catenin, which can then translocate 
into the nucleus and promote the transcription of pro-epithelial to mesenchymal 
transcription (EMT) factors (95). In conjunction with constitutive activation of 
receptor tyrosine kinases, loss of E-cadherin can cement the mesenchymal 
phenotype in cancer cells (96). Moreover, sE-cad can induce cell migration, 
invasion, and signaling (reviewed in Chapter 2).  
The process of EMT in tumor progression allows epithelial cells to lose 
their differentiated non-migratory state and instead become motile and 
metastasize. Once colonized in a new organ, these cancer cells can undergo the 
reverse process of MET (96). In prostate cancer cell lines, xenograft studies of 
EMT allowed prostate cancer cells to metastasize to bone (97). The process of 
EMT and MET can also be observed in prostate cancer patients, where E-
cadherin expression is reduced in localized cancer progression, but when the 
tumors metastasize there is a degree of E-cadherin re-expression in the bone 
metastasis (98). In recent years, EMT has also become a point of interest for 
BPH research. Alonso-Magdalena et al demonstrated that BPH sections 
contained an increased amount of EMT transcription factors such as Slug and 
Snail, suggesting EMT may be contributing to the pathogenesis of BPH (99).  
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Scope of dissertation 
 This dissertation will cover four related topics. First, it will provide a review 
of the literature pertaining to sE-cad generation, presence in patient fluids, and 
the consequences of sE-cad presence in disease (Chapter 2). From there, the 
role of ADAM10-mediated E-cadherin cleavage in untransformed prostate 
biology is examined. These studies utilize two immortalized prostate cell lines 
and demonstrate the role of ADAM10 in E-cadherin cleavage, as well as the 
consequences of sE-cad stimulation on prostate cell lines (Chapter 3). Studies in 
Chapter 3 have defined a novel ADAM10-mediated sE-cad/EGFR signaling axis 
in the prostate (Figure 1-1).  
We also initiated in vivo studies to determine the role of ADAM10 in 
normal prostate biology by generating a prostate specific ADAM10 knockout 
mouse, which has provided Adam10 -/- cell lines and preliminary observations 
regarding consequences of ADAM10 loss in the mouse prostate (Chapter 4). 
Chapter 5 includes preliminary studies pertaining to ADAM inhibitors, the role of 
the ADAM15 EGF-like domain in substrate cleavage, and ADAM10 and 15 
interactions. These studies, although preliminary, provide interesting insight into 
the role of ADAM10 in normal prostate biology, propose a novel function for the 
EGF-like domain of ADAM15, and suggest ADAM10 and 15 exist in a functional 
complex that may have biological significance in benign and malignant prostatic 
disease.  
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Figure 1-1: The ADAM10-mediated sE-cad/EGFR signaling axis.  
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Chapter 2: Soluble E-cadherin: More Than a Symptom of Disease 
 
Abstract 
Epithelial (E)-cadherin is a homophilic adhesion molecule which is 
responsible for maintenance of baso-lateral cell adhesion and polarity. E-
cadherin can be lost from the cell surface by proteolytic cleavage, resulting in the 
generation of an 80kDa fragment referred to a soluble E-cadherin (sE-cad). 
Although originally discovered in the conditioned media of breast cancer cells 
and later verified in the fluids of cancer patients, today sE-cad has been recorded 
in patients with viral and bacterial infections, organ failure, and benign disease. 
The proteases implicated in this cleavage event include members of the 
disintegrin family (ADAM10 and 15), bacterial proteases (gingipains and BFT), 
cathepsins (B, L, S), matrix metalloproteases (MMP-2, 3, 7, 9, and 14), KLK7, 
and plasmin. Stimulus that induces sE-cad generation by ADAMs, MMPs, 
Kallikrein-7 and plasmin in vitro ranges from serum withdrawal to pro-
inflammatory cytokines to growth factors. The cellular or physiologic 
consequences of sE-cad accumulation include the disruption of adherens 
junctions, cellular migration and invasion, induction of MMPs, as well as cell 
signaling, suggesting that sE-cad may contribute to disease progression
16 
 
Introduction 
Epithelial cadherin 
E-cadherin is a homophilic, calcium-dependent, adhesion protein, which is 
expressed at adherens junctions between epithelial cells.  E-cadherin has an 
extracellular region comprised of 5 domain repeats, each domain containing a 
set of seven beta-sheets arranged in an immunoglobulin fold (64). Adhesion is 
achieved by lateral dimerization between E-cadherin molecules on the same cell, 
creating a homodimer which can then interact with an adjacent E-cadherin 
homodimer on a neighboring cell via cadherin repeat 1 (EC1) (65).  
Although E-cadherin is predominantly a homophilic adhesion molecule, it 
also exhibits heterophilic interactions. Of particular interest, E-cadherin can 
associate with CD103 and Killer cell lectin receptor G1 (KLRG1) (66, 68, 100). 
The E-cadherin receptor, CD103 or alphaEbeta7, is located on T lymphocytes and 
helps to target T cells to epithelial cells, where it binds extra cellular domains 
EC1 and EC2 of E-cadherin (66).  Another receptor for E-cadherin, KLRG1, is 
expressed on T cells and natural killer (NK) cells, where the binding of KLRG1 to 
E-cadherin-expressing cells prevents the lysis of epithelial targets (68). The 
interaction between KLRG1 and E-cadherin is mediated by the homodimeric 
interface on EC1, suggesting that monomeric E-cadherin at epithelial cell 
surfaces is responsible for controlling the activation threshold of NK and T cells 
and thereby suppressing immune response (69).  E-cadherin, therefore, can 
serve as an adhesion molecule or a targeting molecule, depending on binding 
partner. Within the cell, E-cadherin interactions support adhesion established 
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through the homodimerization. The cytoplasmic tail of E-cadherin associates 
directly with beta-catenin, p120, and indirectly with alpha-catenin.  Beta-catenin 
binding to E-cadherin provides structural support and aids in transport of E-
cadherin to the baso-lateral plasma membrane (101). The formation of this 
ordered structure allows for binding of alpha-catenin, which can bind actin, 
stabilizing and coordinating actin dynamics at the adherens junction (74, 102). 
p120 binding to E-cadherin also stabilizes the complex and maintains high E-
cadherin levels (75).  From the cytoplasmic side, regulation of E-cadherin 
adhesion can occur by altering the composition of the cadherin-catenin complex, 
the presence growth factors, tyrosine phosphorylation of the cadherin-catenin 
complex, p120 binding to E-cadherin, and the activity of small GTPases and 
proteins which aid in cell polarity determination (76). Additionally, E-cadherin 
adhesion can be disrupted by E-cadherin cleavage in the extracellular or 
cytosolic domains.   
  
E-cadherin cleavage 
 The disruption of E-cadherin function by proteolytic cleavage can occur in 
the extracellular domain or cytosolic tail of E-cadherin. The initial observation of 
E-cadherin cleavage was reported by Wheelock et al who observed an 80kDa 
soluble E-cadherin in the conditioned media of MCF-7 breast cancer cells (103). 
This fragment, containing the five extracellular domains of E-cadherin and 
referred to as sE-cad, could disrupt adherens junctions of mouse mammary 
tumor cells (103). To date, members of the A Disintegrin and Metalloprotease 
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(ADAM) family (ADAM10 and 15), bacterial proteases (gingipains and 
BFT/fragilysin), cathepsins (B, L, S), matrix metalloprotease (MMP) family (MMP-
2, 3, 7, 9, and 14), Kallikrein-7, and plasmin have all been implicated in the 
generation of sE-cad (44, 78, 80-83, 85-87, 89-92, 104-109).  
The extracellular cleavage of E-cadherin can also have implications for the 
intracellular domains. The generation of sE-cad allows the remaining membrane-
bound fragment to undergo further processing by presenilin-1/ gamma-secretase 
complex at the membrane/cytosol interface, which results in the disassembly of 
the adherens junction (110). Additionally, p120, which is critical for the 
association between E-cadherin and gamma-secretase (111), can aid the C-
terminal fragment of E-cadherin in entering the nucleus and binding DNA to 
promote gene transcription (112). This tightly regulated sequential degradation of 
E-cadherin and resulting disassembly of adherens junctions and nuclear 
translocation of the C-terminal fragment, however, is not required for all E-
cadherin cytoplasmic domain processing.    
Apoptosis-induced cleavage of the intracellular domain of E-cadherin by 
calpain and caspase-3 occurs independently of extracellular processing. Calpain 
cleavage of E-cadherin results in a 100kDa E-cadherin fragment which can no 
longer bind beta-catenin and diminishes the survival of prostate cancer cells 
(113). Conversely, caspase-3 can generate a 24kDa cytosolic fragment of E-
cadherin, but requires other metalloproteases to generate the 29kDa fragment 
and sE-cad  (114). The generation of sE-cad, however, is not limited to 
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apoptosis, and there are a variety of stimuli which can induce E-cadherin 
cleavage.  
 
Generation of sE-cad 
Membrane sheddases 
 The proteases capable of extracellular E-cadherin cleavage, referred to as 
sheddases, are a diverse group. While many of these sheddases are 
misregulated or overexpressed in disease, the author has limited her descriptions 
to cell systems and diseases where sE-cad is present in conditioned media of 
cells or patient fluids. To date, no sheddase unique to E-cadherin has been 
identified, and the sheddases described below are also responsible for cleavage 
and shedding events beyond sE-cad generation (Table 2-1).  
 
ADAM family 
 The human ADAM family consists of 25 members whose expression 
varies across tissues. Functionally, the ADAMs play roles in adhesion and 
substrate cleavage.  To that end, ADAMs are made up of an inhibitory 
prodomain, a zinc-dependent metalloprotease domain, a disintegrin domain, a 
cysteine-rich domain, an EGF-like domain, a transmembrane domain and a 
cytoplasmic tail. Within the ADAM family, only ADAM10 and 15 have been 
implicated in E-cadherin shedding (44, 83, 85, 104).  
ADAM10 can be found in mesenchymal stem cells, placenta, blood, 
myeloid cells, bladder, and bone marrow myeloid cells, where it is predominantly 
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a sheddase with a substrate list featuring 27 proteins, including E-cadherin (26).  
In terms of E-cadherin cleavage in the skin, ADAM10 has been implicated in 
generating sE-cad in normal keratinocytes as well as melanoma cell lines. In 
keratinocytes, Maretzky et al examined the soluble 80kDa form and 37kDa C-
terminal fragment (CTF) associated with the membrane and determined that 
ADAM10 constitutively sheds sE-cad (104). ADAM10-dependet shedding of E-
cadherin could be induced by the pro-inflammatory cytokines IL-1 beta, TNF-
alpha, IFN-gamma, TGF-beta, and lipopolysaccharide (LPS).  Additionally, 
biopsies from eczema patient lesions revealed elevated levels of ADAM10 and 
CTF (104). ADAM10 also exists in its active form in melanoma cell lines (85), but 
to date, no inhibitor or loss of function studies of ADAM10 in melanoma cell lines 
in terms of sE-cad generation have been undertaken. However, ADAM10 is up-
regulated in metastatic melanoma compared to primary melanoma (115), and it 
is possible that it is the sheddase responsible for E-cadherin cleavage.  
ADAM10 has also been implicated in shedding E-cadherin in response to 
Helicobacter (H.) pylori infection of gastric cancer cell lines (83). Previously, H. 
pylori infection was found to correlate with increased ADAM10 expression in 
gastric cancer patient samples and to induce ADAM10 expression in gastric 
cancer cell lines (116). Indeed, chemical inhibition or shRNA mediated 
knockdown of ADAM10 resulted in decreased sE-cad generation in response to 
H. pylori infection, suggesting that induction of ADAM10 by H. pylori in the gut 
promotes E-cadherin cleavage (83).  
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Recent work in our lab has determined that in benign prostatic hyperplasia 
(BPH) cells, epidermal growth factor (EGF) can induce sE-cad generation in 
response to EGF in ADAM10-dependent manner (manuscript submitted to 
Cellular Signaling, Chapter 3).  In a paper by Arima et al, the authors 
demonstrated that ADAM10 is highly expressed on the cell surface of BPH 
patient samples versus cancer samples where ADAM10 resided predominantly 
within the nucleus (36). This suggests that based on location alone, ADAM10 is 
likely a major sheddase of E-cadherin in BPH, but not in prostate cancer.  
 Unlike ADAM10, ADAM15 has only four reported substrates, but it also 
has three integrin binding partners (26). The expression of ADAM15 is 
widespread in the human tissues, but it is the highest in mesenchymal stem cells 
and the urogenital system (26). It is also significantly over-expressed in breast, 
prostate, and lung cancer (44). Najy et al demonstrated that serum withdrawal 
from breast cancer cells induced E-cadherin cleavage by ADAM15, and the 
generation of sE-cad could be abrogated by shRNA knockdown of ADAM15 or 
increased by ADAM15 over-expression (44). Our unpublished observations also 
suggest that prostate cancer and bladder cancer cells shed sE-cad in response 
to serum withdrawal in an ADAM15- dependent manner as well. Additionally, in 
untransformed mouse cells, ADAM15 knockout prostate cell lines fail to shed 
appreciable amounts of sE-cad as compared to wild-type control cell lines, 
suggesting ADAM15 can also cleave E-cadherin in mouse prostate epithelial 
cells (unpublished observations). 
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Bacterial proteases (Gingipains, BFT/fragilysin)  
 Gingipains (HRgpA, RgpB, and Kgp) are secreted cysteine proteases 
which are encoded in the genome of Porphyromonas gingivalis (P. gingivalis). P. 
gingivalis has been reported to contribute to adult periodontitis in two ways. First, 
by infecting epithelial cells, P. gingivalis can influence signal transduction and 
innate immune response (117). Independent of epithelial cell infection, P. 
gingivalis can disrupt adherens junctions, allowing for infection of underlying 
tissues (118). The disruption of the adherens junction is believed to be mediated 
by Kgp cleavage of E-cadherin (105). Although HRgpA and RgpB can also 
cleavage of immunoprecipitated E-cadherin, they are unable to process E-
cadherin from the cell surface of Madin-Darby canine kidney (MDCK) cells (105).  
 Another bacterial protease which has been implicated in E-cadherin 
cleavage is from Bacteroides fragilis (B. fragilis). B. fragilis produces an 
enterotoxin referred to as B. fragilis toxin (BFT) or fragilysin. Treatment of 
HT29/C1 colorectal adenocarcinoma cells with BFT results in the generation of 
the 33kDa and 28kDa cytoplasmic E-cadherin fragments (106). Although the 
authors demonstrated that BFT did not enter the cells and hence could not 
generate the cytoplasmic fragments, they were unable to observe BFT-mediated 
cleavage of their recombinant E-cadherin and generation of sE-cad (106). These 
studies suggest that E-cadherin cleavage may be an important step in bacterial 
infection.   
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Cathepsins 
 Cysteine cathepsins are intracellular proteases which are responsible for 
protein degradation in the lysosome and play critical roles in apoptosis, 
autophagy, and necrosis (119). Although located within the lysosome under 
normal conditions, an emerging body of evidence suggests cathepsins can be 
mislocalized or released from the cell. For example, release of active cathepsin B 
has been demonstrated in mechanically injured mouse gut (120), and 
procathepsin B can interact and localize with annexin II tetramer on the 
extracellular surface of human breast cancer and glioblastoma cells (121). These 
studies suggest that in the context of disease, cathepsins may be a viable 
candidate for extracellular cleavage of E-cadherin.  
 Interest in cathepsin cleavage of E-cadherin originated with the 
observation that pancreatic tumors from cathepsin B, L, or S knockout mice on 
the background of the RT2 pancreatic cancer mouse model retained expression 
of E-cadherin, suggesting E-cadherin processing was deficient (107).  Indeed, 
when Gocheva et al combined recombinant E-cadherin with active cathepsins B, 
L, or S,  E-cadherin was cleaved to a 64kDa extracellular fragment (107). 
Because cathepsins B and L are upregulated during pancreatic cancer 
progression (107) and high cathepsin B expression is an independent prognostic 
marker for pancreatic cancer recurrence (122), it is likely that the mislocalized 
cathepsins play a role in E-cadherin cleavage in pancreatic cancer.    
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Kallikrein-7 
 Kallikerein-7 (KLK7) is serine proteases which is normally expressed in 
the salivary gland, nervous system, kidney, mammary gland and skin and to a 
lesser extent in the uterus, thymus, thyroid, placenta, and trachea (123). It is not 
expressed in the normal pancreas, but it is dramatically over-expressed in 
pancreatic cancer (86). In pancreatic cancer cell line cultures, recombinant KLK7 
was capable of cleaving E-cadherin in vitro and from the cell surface of 
pancreatic cancer cell lines (86). Because of its dramatic upregulation in 
pancreatic cancer, it is likely that KLK7 is a responsible protease for E-cadherin 
cleavage in pancreatic cancer patients.  
  
MMP family 
 Like the ADAM disintegrins, the MMPs are zinc dependent proteases (26, 
124). While the majority of the MMP family are secreted, a subset of the MMP 
family, the membrane type (MT) MMPs remain associated with the cell 
membrane (124).  MMP activity is tightly controlled by MMP gene transcription, 
pro-enzyme activation, and MMP inhibition (124).  In E-cadherin cleavage, five 
MMPs have been implicated: MMP-2, MMP-3, MMP-7, MMP-9 and MT1-MMP 
(MMP-14).  
 In prostate cancer, MMP-2 is an independent predictor of patient survival. 
Early immunohistochemical studies of MMP-2 in prostate cancer patients 
demonstrated that epithelial expression of MMP-2 in prostate tumors correlated 
with a decrease in patient survival (125). In vitro, MMP-2 has been implicated in 
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sE-cad generation in prostate cancer cells which have been transfected with 
protein kinase D1 (PKD1) (82). The in vitro data and the over-expression of 
MMP-2 in prostate cancer suggest MMP-2 is a possible candidate for E-cadherin 
shedding in prostate cancer.  
MMP-3 shedding of E-cadherin has been reported in mouse and human 
mammary cells. Early studies by Lochter et al revealed that an auto-activating 
MMP-3 mutant transfected into mouse mammary cells resulted in the shedding of 
sE-cad from their cell surface (81, 87). Later analysis of MMP-3 and 7 by Noe et 
al demonstrated that E-cadherin can be cleaved in vitro by these 
metalloproteases in breast cancer cells as well (87). In patients, MMP-3 is over-
expressed and activated in breast cancer samples versus normal tissue (126, 
127), suggesting MMP-3 could be an E-cadherin sheddase in breast cancer. 
 MMP-7 generation of sE-cad has been reported in prostate, gastric, and 
breast cancer cells, as well as in a mouse model of lung injury (80, 87, 89, 108). 
In prostate cancer and gastric cancer cell lines, treatment of cells with hepatocyte 
growth factor/scatter factor (HGF/SF), results in the release of MMP-7 and 
cleavage of E-cadherin (80, 108). When MMP-7 levels are decreased by short 
hairpin (sh) RNA against MMP-7, sE-cad generation is lost (80, 108). Prostate 
cancer patients with advanced disease have more active MMP-7 in their serum 
(128), while for gastric patients, expression of MMP-7 correlates with a decrease 
in patient survival and more advanced stage (129) . In breast cancer cell lines, E-
cadherin can be cleaved in vitro by MMP-7 (87), and in patients MMP-7 positive 
tumors by immunohistochemistry correlate with a worse prognosis (130). 
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Because MMP-7 is over-expressed in breast, prostate, and gastric cancer, it is 
possible that MMP-7 is major sheddase of E-cadherin in these cancers.  
MMP-7 over-expression is not unique to cancer, and can occur in 
response to injury. In a mouse lung injury model using bleomycin, MMP-7 is 
dramatically upregulated in injured lung epithelium (89, 131). McGuire et al also 
demonstrated that MMP-7 knockout mice did not generate sE-cad from wounded 
trachea explants, unlike their wild-type controls, implicating that the upregulation 
of MMP-7 in response to wounding is responsible for sE-cad generation in this 
model (131).  MMP-7 upregulation occurs in pulmonary fibrosis patients (132), so 
MMP-7 generation of sE-cad may play a role in disease progression. 
Interestingly, in these studies only the lung cancer cells that were transfected 
with an auto-activating MMP-7 produced the active form of the enzyme; native 
full length cDNA for MMP-7 did not produce active enzyme (89), suggesting that 
there is a missing mediator required for MMP-7 activation in these epithelial lung 
cancer cells.  
 MMP-9 shedding of E-cadherin appears in ovarian, head and neck, and 
prostate cancer cell lines. MMP-9 expression is a negative predictor for survival 
in ovarian cancer, head and neck cancer, as well as prostate cancer (133-135). 
In ovarian cancer cell lines, aggregation of collagen binding integrins alpha2beta1 
and alpha3beta1 induces MMP-9 expression which promotes E-cadherin 
shedding (90).  Early studies of MMP-9 in head and neck cancer patients 
demonstrated that serum levels of MMP-9 were highest in patients with more 
advanced disease (135) and in vitro, stimulation of head and neck cell lines with 
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EGF demonstrated increased expression of MMP-9 and increased sE-cad (109). 
Finally, the re-expression of PKD1 in prostate cancer cells also resulted in 
increased MMP-9 expression, which correlates with increased sE-cad 
generation, and could be abrogated by the addition of MMP-9 inhibitors (82). 
Based on the high expression of MMP-9 in ovarian, head and neck, and prostate 
cancer patients, it is likely that MMP-9 contributes to sE-cad levels in these 
patients.  
 MT1-MMP (MMP-14) has been implicated in sE-cad generation in a model 
of kidney ischemia.  Normal rat kidney cells under ischemic conditions generated 
sE-cad which, by inhibitor studies, was not mediated by MMP  -1, -3, -8, or -9 
(91). Covington et al did, however, observe an increase in MT1-MMP expression 
in response to ischemia, and determined that loss of MT1-MMP by shRNA 
decreased sE-cad accumulation, confirming that sE-cad can be generated by 
MT1-MMP under these conditions (91).   In a mouse model of hind-limb 
ischemia,  active MT1-MMP was up-regulated in the ischemic limb as compared 
to the control, sham operated limb (136), suggesting that MT1-MMP may be the 
sheddase of E-cadherin under ischemic conditions.  
 
Plasmin 
 Plasmin is a serine protease with limited specificity, which can act on 
fibrin, fibrinogen, extracellular matrix components, and pro-forms of growth 
factors either directly or by activating metalloproteases (137). It is also a 
downstream component of the urokinase-type plasminogen activator (uPA) 
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system, which can be activated in ovarian cancer cells by Lysophosphatidic acid 
(LPA) (138). LPA is found in high concentration in ovarian cancer ascites and 
promotes growth in ovarian cancer cell lines in vitro and in vivo (139). In ovarian 
cancer cell lines, LPA activates the urokinase-type plasminogen activator (uPA) 
which activates plasmin, resulting in E-cadherin cleavage (92). Although the 
authors could not rule out metalloproteases downstream of plasmin, they did 
note that in their studies, LPA only increased pro-MMP-9 slightly, suggesting that 
plasmin may be directly acting upon E-cadherin (92). Other work in MDCK cells 
demonstrated that treating cells with plasmin can generate sE-cad and this 
process can be inhibited by the addition of aprotinin, a serine protease inhibitor 
(78). Since uPA system disregulation correlates with worse outcome in ovarian 
cancer patients (140), it is likely that an elevated level of plasmin in these 
patients generates sE-cad.   
 
Unattributed sheddase activity 
 In addition to the studies which successfully define sE-cad sheddases, 
other studies demonstrate the existence of sE-cad as a consequence of stimuli, 
but do not identify the responsible protease. In these studies, the protease could 
be one of the aforementioned sheddases or it could be a novel sheddase. Ito et 
al demonstrated that calcium influx by serum withdrawal or ionomycin treatment 
allowed for sE-cad to accumulate in the conditioned media of cancer cells (141). 
Although they never identified a responsible sheddase, they did report only the 
membrane fractions and not cell supernatants were capable of cleaving E-
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cadherin in vitro, suggesting a membrane bound metalloprotease was required 
and ruled out the classical MMPs in direct cleavage (141). 
 In the breast cancer MCF-7/AZ cell line, the phorbol ester PMA can 
induce the shedding of E-cadherin by a metalloprotease that is sensitive to tissue 
inhibitor of metalloprotease-2 (TIMP-2) inhibition (87).  In the same study, 
immunopurified MMP-3 and MMP-7 are shown to cleave E-cadherin directly and 
from the cell surface of MDCK cells (87), but a direct sheddase from PMA 
induction was not demonstrated. Other studies of apoptotic MDCK cells also 
implicated a metalloprotease which was sensitive to TAPI, an ADAM17 inhibitor 
which can inhibit other metalloproteases (114). 
 Several studies have determined that the accumulation of sE-cad may be 
a biomarker for tissue damage and predict surgical outcome (142, 143).  Goto et 
al applied this to a model of lung transplantation in rats and observed that rats 
with transplanted lungs had a higher level of sE-cad than the sham operated rats 
(144). Again, no direct evidence implicates a sheddase, but other studies have 
implicated MMP-7 in rodent lung damage studies (89, 131).  
 
Proteolytic cascades 
 The study of sE-cad shedding is greatly complicated by the existence of 
proteolytic cascades, particularly those involving the MMPs and the uPA system. 
Synthesized as zymogens, MMPs require proteolytic processing to become 
active, and this process can be mediated by other MMP family members. As 
summarized in reviews by Egeblad and McCawley: MMP-2 can generate active 
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MMP-1, 2, 9, and 13; MMP-3 can generate active MMP 1, 3, 7, 8, 9, and 13; 
MMP-7 can generate active MMP-1, 2, 7 and 9; MMP-9 can generate active 
MMP-2; finally, MMP-14 can generate active MMP-2 and 13 (145, 146). Based 
on the ability of MMPs to activate other family members, studies examining 
upstream MMPs may have difficulty distinguishing effects due to catalytic activity 
on a substrate by the upstream MMP versus catalytic activation of a downstream 
MMP and its subsequent cleavage of the substrate. In the uPA system, the 
proteolytic cascade is more manageable. Here, uPA converts plasminogen to 
plasmin, which can then cleave proMMP-2 and 9 to active MMP-2 and 9 (147). 
Because plasmin is a serine protease which can activate zinc-dependent 
metalloprotease, these different enzyme classes allow for specific inhibitors and 
easier determination of the responsible sheddase. The existence of proteolytic 
cascades coupled with the redundancy observed in E-cadherin cleavage may 
explain why sE-cad is observed in multiple patient conditions.  
 
 
 
 
 
 
 
 
31 
 
 
Table 2-1: E-cadherin sheddases 
Sheddase Stimulus System Studies Ref  
ADAM10 IL-1-beta, TNF-alpha, 
IFN-gamma, TGF-beta, 
Lipopolysaccharide (LPS)
None (growing cultures) 
Helicobacter pylori 
infection 
 
EGF 
Normal 
keratinocytes 
 
Melanoma cell line 
Gastric carcinoma 
cell line 
Benign prostatic 
hyperplasia cell 
line 
In, si 
 
 
Exp. 
si, In 
 
In, sh 
(104)
A 
 
 
(85) 
(83) 
 
B 
ADAM15 Serum withdrawal Breast cancer cell 
line 
Prostate cancer 
cell line 
Bladder cancer 
cell line 
OE, sh, 
 
OE, sh, 
KO 
OE, sh  
(44) 
 
C 
 
C 
BFT 
fragilysin 
B. fragilis infection Colorectal cancer 
cell line 
PP (106)
A 
Cathepsins 
(B, L, S) 
 Ms pancreatic 
cancer model 
RP (107) 
Gingipains P. gingivalis infection Canine kidney cell 
line 
PP (105) 
MMP-3  
Stromelysin 
? 
 
? (Activated mutant) 
Breast cancer cell 
line 
Ms mammary cell 
line 
RP 
aOE, In 
(87) 
(148) 
MMP-7  
Matrilysin 
HGF 
 
HGF 
 
Lung injury (bleomycin) 
 
 
? 
Gastric cancer cell 
line 
Prostate cancer 
cell line 
Lung cancer cell 
line, mouse lung 
injury 
Breast cancer cell 
line 
Ind, sh 
 
RP, si 
 
aOE, In, 
KO 
 
RP 
(108) 
 
(80)  
 
(89) 
 
 
(87) 
MMP-9 Collagen binding 
integrins (alpha2beta1, 
alpha3beta1) interaction 
EGF 
 
PKD1 
Ovarian carcinoma 
cell line 
 
Head and neck 
cancer cell line 
Prostate cancer 
cell line 
Ind, In, 
FBA 
 
Ind, si  
 
In 
(90) 
 
 
(79) 
 
(82) 
MT1-MMP  Ischemia (mineral oil Normal rat kidney In, FAB, (91) 
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ARead-out is the C-terminal fragment, not sE-cad. B Manuscript submitted. C Unpublished 
observations D Original report sE-cad EADAM17 inhibitor which can block other 
metalloproteases. In: inhibitor. si: siRNA. sh: shRNA.  Exp: expression. OE: Over-
expression. RP: recombinant protein. PP: Purified protein. Ind: Induction of 
metalloprotease. aOE: auto-activating mutant metalloprotease. KO: knockout mouse. 
FBA: function blocking antibody 
 
 
sE-cad is present in a variety of patient conditions 
sE-cad was first observed in the conditioned media of MCF-7 cells by 
Wheelock et al (103), and since then, many studies have been conducted on 
patient fluids to determine whether sE-cad could serve as a biomarker for 
disease. The initial report by Katayama et al determined that levels of sE-cad do 
not vary significantly between men and women or different age groups (149). 
Although the initial focus on sE-cad was as a cancer biomarker for disease, 
progression, or recurrence, today there are several studies which describe the 
presence of sE-cad in other disease states, such as HIV infection and benign 
prostatic disease (150, 151). In order to be included, studies must have reported 
on the presence of sE-cad in more than one patient. For example, the initial 
MMP-14 overlay) cell line sh 
Plasmin Lysophosphatidic acid 
(LPA) 
None (growing cultures) 
Ovarian carcinoma 
cell line 
Canine kidney cell 
line 
In 
 
RP, In 
(92) 
? Calcium influx, ionomycin Lung tumor cell 
line 
In (141) 
? Ischemia (lung 
transplant) 
Rat lung 
transplantation 
 (144) 
TIMP-2 
sensitive 
? 
TAPIE 
sensitive 
Phorbol ester (PMA) 
 
Serum withdrawal 
Apoptosis (staurosporine, 
camptothecin) 
Breast cancer cell 
line 
Breast cancer cell 
line 
Canine kidney cell 
line 
In 
 
In 
In 
(87) 
 
(103)
D 
(114) 
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report of sE-cad in patient samples by Katayama et al included a report for one 
pancreatic and one ovarian cancer patient (149), which was not sufficient for 
inclusion in this review (Table 2-2). 
 
Cancer 
Bladder 
 Sera from newly diagnosed bladder cancer patients have significantly (P = 
0.017) higher levels of sE-cad than normal controls (1,013 ng/ml v. 3,955 ng/ml) 
(152).  Additionally, high levels of sE-cad correlate with higher grade, number of 
tumors, and recurrence but not tumor bulk (152).  In the urine, healthy controls 
exhibited 582 ng/ml of sE-cad in the urine, while bladder cancer patients 
averaged 1,272 ng/ml across all stages and grades (P < 0.001 ) (153). The 
authors suggested, however, that using total protein in urine is equally effective 
at this determination (153).  In a later study, Shi et al found that urine levels of 
sE-cad normalized to creatinine were significantly (P < .01 ) lower in normal 
(1.306 mg/mol) versus cancer samples (3.724 mg/mol), and that samples from 
recurrent patients (10.497 mg/mol) had significantly (P < 0.01 )  higher levels of 
sE-cad than primary tumors (154). Additionally, they found that sE-cad correlated 
well with tumor grade, but not with stage, size, and the number of tumors (154). 
Based on these data, both serum and urine concentrations of sE-cad can be 
used to stratify bladder cancer patients.  
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Colorectal 
 In colorectal cancer, the initial report determined that there was no 
statistically significant difference between sE-cad levels from healthy controls 
and colorectal cancer patients (155). Later, Willmanns et al found that sE-cad 
levels were statistically different between healthy controls versus benign disease 
(P = 0.005 ) versus cancer (P = 0.009 ) (3,476 ng/ml; 5,248 ng/ml; 5,495 ng/ml) 
and that  the highest levels were found in metastatic patients (156). They also 
observed that in this cancer cohort, patients with renal or hepatic failure had high 
levels of sE-cad and that patients who had been treated with chemotherapy had 
lower sE-cad levels compared to untreated patients (156).  From these data, it is 
apparent that while sE-cad serum levels may be useful in determining cancer 
spread in untreated patients, it would be important to rule out organ failure or 
dysfunction.  
 
 Esophageal squamous cell carcinoma 
 The recent study in squamous cell carcinoma compared the pre-operative 
levels of sE-cad for patients who had surgery alone to those patients who had 
chemoradiation therapy (CRT) before surgery. Patients in the surgery alone arm 
had significantly (P = 0.032) higher (5,108 ng/ml) levels of sE-cad than patients 
who had already received chemoradiation therapy (3,688 ng/ml) (157). This 
decrease of sE-cad levels after chemotherapy agrees with data from colorectal 
cancer patients (156), and suggests sE-cad could be used to monitor patient 
response to therapy. For the patients who received surgery, levels of sE-cad 
35 
 
higher than the median pre-surgery sE-cad concentration correlated with a 
decrease in survival; however, there was no prognostic significance for patients 
who had undergone neoadjuvant CRT (157). Therefore, sE-cad as prognostic 
marker for esophageal squamous cell carcinoma would be limited to patients 
who have yet to undergo any treatment (157).  
 
Gastric 
 Initials reports of elevated sE-cad in gastric cancer came from Katayama 
et al (2,000 ng/ml vs. 3,515 ng/ml; P < 0.0001) (149), which were confirmed by 
Gofuku et al (158). Later studies by Chan et al demonstrated that not only was 
sE-cad elevated in gastric cancer patients (5,616 ng/ml vs. 9,344 ng/ml; P = 
0.001) but also that this correlated with tumor size and poor outcome markers 
(159). When Chan et al determined the optimal sensitivity and specificity of sE-
cad following tumor resection by ROC analysis, they determined 10,000 ng/ml as 
a point of elevated sE-cad. Once a patient’s serum concentration of sE-cad 
exceeded 10,000 ng/ml, the tumor would eventually recur (160). On average, 
elevated sE-cad levels predated the recurrence by 13 months (160). Most 
importantly, the sensitivity of this test was similar in patients with more and less 
advanced disease (160).  In another study, Chan et al determined that a pre-
therapeutic 10,000 ng/ml sE-cad concentration was also a predictor of survival, 
where 90% of patients whose sE-cad levels were above the cutoff had a survival 
time of less than three years (P = 0.009) (161). Chan et al acknowledged the 
substantial differences between normal sE-cad levels in the Katayama study 
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(149) and theirs (159) by suggesting that the differences may be attributed to the 
different populations used in the study. Later studies by Pedrazzani et al 
determined that while sE-cad is indeed elevated in gastric cancer patients as 
previously reported, there was a linear increase with sE-cad levels in normal 
controls and gastric tumor patients over time (162), which is inconsistent with 
previous observations (149).  
sE-cad levels in gastric cancer patients can be decreased by resection or 
therapy. Resection alone can significantly (P < 0.0001)  reduce sE-cad levels 
(158). Later studies by Zhou et al demonstrated that if surgery was coupled with 
neoadjuvant Celecoxib therapy, patients showed a significant (P < 0.01) 
decrease in sE-cad levels during therapy and a significant (P < 0.01)  decrease in 
sE-cad post-surgery (163). Based on the data, the use of sE-cad in gastric 
cancer would be quite informative for patient survival and recurrence, particularly 
since there is a significant amount of time between elevated sE-cad levels and 
actual recurrence, which would allow for appropriate therapeutic intervention 
(160). Additionally, future studies of sE-cad in gastric patient response could 
provide an early indication of failed therapy and appropriate therapeutic 
intervention.  
 
Liver 
 Patients with liver cancer have an increased level of sE-cad (P <0.0001; P 
< 0.05) (149, 164). The levels reported, however, are quite disparate with normal 
controls being reported as 2000 ng/ml or 5,798 ng/ml and cancer levels at 5550 
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ng/ml versus 10,759 ng/ml (149, 164). Soyama et al also demonstrated that 
levels of sE-cad in the serum of patients did not correlate with levels of E-
cadherin in hepatic lesions, tumor markers, size, number, vascular invasion, 
stage, gender, age, or viral status (164). However, patients with levels higher 
than 8,000ng/ml were more likely to recur and metastasize (P < 0.05) (164). It 
appears that sE-cad could be a useful biomarker for disease spread and 
recurrence in liver cancer.  
 
Non-epithelial 
 sE-cad levels can also be found in patients with non-epithelial tumors such 
as leukemia, multiple myeloma, and leiomyosarcoma. Patients with leukemia 
(myelogenous, monocytic, lymphatic) have increased levels of sE-cad (P < 0.01), 
as do patients with leiomyosarcoma (P < 0.05) (144).  Multiple myeloma patients 
have five times higher levels of serum sE-cad than control samples (P < 0.0001)  
(165). sE-cad is also a survival predictor, where patients with levels of sE-cad 
below 3,000 ng/ml lived longer (P = 0.0015), and an increase in sE-cad of 
100ng/ml increased their risk of death from multiple myeloma by 6% (P = 0.013) 
(165). In a non-epithelial setting, the source of sE-cad cannot come from the 
tumor cells themselves; instead it is more likely due to the tumors invasion into 
epithelial tissue. For example, leiomyosarcomas can occur in the smooth 
muscles cells of the stomach and grow into the stomach proper, resulting in 
epithelial tissue damage and shed sE-cad. In new multiple myeloma patients, sE-
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cad levels could be used as a prognostic marker because high levels correlate 
with poor disease outcome (165).  
 
Non-small cell lung (NSCLC) 
 In NSCLC patients, sE-cad serum levels are much higher than in healthy 
volunteers (3,455 ng/ml vs. 1,015 ng/ml; P < 0.001) and the highest levels of sE-
cad also correlate with metastasis (P < 0.001) (166). There was, however, no 
statistically significant difference between the levels of sE-cad and histological 
type of cancer (adenocarcinoma, squamous cell carcinoma, or large cell 
carcinoma), sex, or smoking habit (166).  Later studies confirmed these 
observations in NSCLC, but also demonstrated elevated levels of sE-cad in small 
cell lung cancer (SCLC) and that increasing levels of sE-cad correlated with 
metastasis in SCLC (167). This suggests that while sE-cad might be useful in 
determining whether a patient has metastatic disease, it would not be useful in 
disease classification.  
  As in gastric cancer, sE-cad levels in NSCLC can decrease following 
therapy. Reckamp et al evaluated serum sE-cad levels in NSCLC patients before 
and after Celecoxib and Erlotinib treatment (168). Although there was no 
difference between sE-cad levels between patients with partial response, stable 
disease, and progressive disease initially, after 8 weeks of therapy, patients who 
achieved a partial response had significantly lower levels of sE-cad than those 
with stable or progressive disease (P = 0.021) (168), suggesting sE-cad may be 
a useful marker for therapeutic response.  
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Ovarian 
 In an early report of sE-cad levels in ovarian cancer, Darai et al 
determined that the levels of serum sE-cad between luteal cyst, dermoid tumor, 
cystadenoma and malignant tumors did not vary significantly (169). Conversely, 
when the cyst fluid was examined, the levels of sE-cad were significantly (P = 
0.001) higher in patients with malignant versus benign disease (169). Other 
researchers examined the ascites of benign ovarian disease or ovarian cancer 
patients and determined that patients with ovarian cancer had very high levels of 
sE-cad (P < 0.000005) (90). Gil et al later confirmed the presence of sE-cad in 
malignant ascites of women with advanced ovarian cancer (92). Because serum 
sE-cad levels fail to distinguish between benign and malignant disease, the use 
of sE-cad as a biomarker in ovarian cancer would have to be limited to cyst fluid 
or ascites.  
 
Prostate 
 The initial report of sE-cad in prostate cancer by Kuefer et al 
demonstrated the presence of sE-cad in prostate cancer tissues, with increased 
expression in metastatic deposits and significantly elevated serum levels in 
patients with metastatic disease (P < 0.001) (170). Later studies comparing BPH, 
localized and metastatic prostate cancer sE-cad concentrations to healthy 
controls demonstrated significant differences (normal v. BPH P = 0.023; BPH v. 
localized prostate cancer P =0.011; localized v. metastatic P < 0.001) (151). In 
this study, Kuefer et al also evaluated sE-cad as a biomarker to predict outcome.  
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Surprisingly, sE-cad at the time of diagnosis could predict biochemical failure, 
mainly that localized disease with high levels of sE-cad (above 7.9ug/l) would 
likely result in late biochemical failure (P < 0.05) (151).  In prostate cancer, 
therefore, sE-cad may be useful in stratifying patients, but the greatest use might 
be in categorizing high-risk for recurrence patients.  
 
Skin 
Levels of sE-cad in different types of skin cancer vary according to type. In 
basal or squamous cell carcinoma, the levels of serum sE-cad did not vary 
significantly from the healthy controls (171). In Paget’s disease, the levels of sE-
cad were significantly elevated above control samples, but only once the disease 
became invasive (171). In melanoma, early reports suggested that levels of sE-
cad were elevated once patients had metastatic disease (171).  Later studies 
confirmed that levels of sE-cad in melanoma patients were higher than in normal 
controls (3,198 ng/ml v. 4,975 ug/ml; P < 0.05), and the expression of sE-cad 
correlated with rising S100 values, indicating melanoma progression (P < 0.05) 
(85). Interestingly, high sE-cad levels were observed in some patients with low 
levels of S100, which the authors suggest, may be an indication that generation 
of sE-cad may serve as an early marker of progression for a subgroup of patients 
(85).  
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Non-cancer  
 Although sE-cad has been extensively studied as a biomarker in cancer, it 
has also been observed and evaluated as a biomarker for non-cancer conditions 
such as BPH, dermatitis, psoriasis, acute pancreatitis, diabetes, and diabetic 
nephropathy. In BPH patients, the levels of sE-cad were significantly higher than 
in normal control patients (P = 0.023) , but not as high as those patients with 
prostate cancer (151). Similarly, patients suffering from acute psoriasis and 
dermatitis had elevated levels of sE-cad in their serum, but unlike skin cancers 
where sE-cad levels correlated with invasion (85, 171), in the non-cancer setting, 
sE-cad correlated with the severity of the disease (171).   
Serum concentrations of sE-cad are also predictive of acute pancreatitis. 
As of 2009, when the study was conducted, the standard tests for acute 
pancreatitis were poor predictors of severity (172), so Sewpaul et al 
hypothesized that because patients with systemic inflammatory response shed 
sE-cad (142), sE-cad could be a used as a marker for acute pancreatitis. Indeed, 
sE-cad levels were elevated in patients with mild acute pancreatitis (7,358 ng/ml) 
versus acute severe pancreatitis (17,789 ng/ml) versus healthy controls (5,181 
ng/ml) (P = 0.0166; P = 0.0039) (172). The levels of sE-cad in severe acute 
pancreatitis were also significantly higher (P = 0.0073) than other abdominal 
inflammatory pathologies (acute diverticulitis, perforated duodenal ulcer, 
cholangitis, acute appendicitis, and acute cholecystitis), suggesting that sE-cad 
levels could be a specific predictor for acute severe pancreatitis (172). Most 
importantly, this study demonstrated that sE-cad levels at 12 hours from onset of 
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pain could predict the severity of pancreatitis, allowing for appropriate 
intervention (172). 
 In diabetes, levels of sE-cad in the sera or urine of healthy controls versus 
diabetic patients do not show significant difference (149, 173). However, sE-cad 
levels in the urine may be useful in determining which diabetic patients are 
suffering from diabetic nephropathy (173). The urine levels of diabetic patients 
with normoalbuminuria, microalbuminuria, and macroalbuminuria vary 
significantly (P < 0.001) , suggesting that sE-cad might be a biomarker for 
diabetic nephropathy (173).   
  
Infection 
For HIV infection, the levels of sE-cad correlate with viral load in patients. 
Interest in sE-cad in HIV infection arose from the observation that the intestine is 
a site of increased permeability in infected patients, suggesting a disruption in E-
cadherin function (150). Indeed, high HIV viral titers significantly (P = 0.004) 
correlate with high levels of serum sE-cad, suggesting that sE-cad is a marker for 
severity of infection (150). Conversely, acute hepatitis does not elevate the levels 
of sE-cad above controls (149).  
 
Organ dysfunction 
 The levels of sE-cad are significantly (P 0.0019) higher in patients with 
sepsis and organ dysfunction as compared to normal controls, and tend to 
increase with the amount of organ dysfunction and sepsis in the patient (142). In 
43 
 
surgery, the levels of sE-cad can be used as a biomarker of tissue injury and 
inflammation. For example, a comparison of open to laparoscopic 
cholecystectomy demonstrated that the less invasive laparoscopic procedure 
resulted in less sE-cad generated (P = 0.04) (143). These studies suggest that 
sE-cad levels in patient serum can be used to determine the extent of tissue 
damage and systemic inflammatory response.  
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Table 2-2: sE-cad can be found in the fluids of patients with multiple 
conditions 
Patient 
diagnosis 
Type sE-cad 
correlates 
with: 
Source sE-cad Levels 
(ng/mL) 
Ref 
Cancer Bladder Cancer, 
grade, 
number, 
recurrence 
Cancer 
 
Cancer, 
grade 
Recurrence 
 
Serum 
 
 
 
Urine 
 
Urine 
N: 1013 
C: 3955 
 
 
N:  .516 mg/mol 
C:  1.536 mg/mol 
N: 1.306 +/- 1.249 
mg/mol 
C: 3.724 +/- 1.892 
mg/mol 
R: 10.497 +/- 7.47.1 
mg/mol 
(152) 
 
 
 
(153) 
 
(154) 
 Colorectal Cancer, 
Progressio
n 
 
Not 
significant 
Serum 
 
 
Serum 
N1: 3467 
B1: 5248 
C1: 5495 
N: 3.53 
C: 3.17 
(156) 
 
 
(155) 
 Esophageal 
squamous cell 
carcinoma 
Survival 
(surgery 
only) 
Serum PreOp:  5108.96 
PreCRT: 3688.932 
PostCRT: 3981.029 
(157) 
 Gastric Cancer 
 
Cancer 
 
Recurrence 
Survival 
Cancer 
Serum 
 
Serum 
 
Serum 
Serum 
Serum 
N: 2515 +/- 744 
C: 4735 +/- 2310 
N: 5616 
C: 9344 
sE-cad above 10000
sE-cad above 10000 
N: 2000 
C: 3510 +/- 1790 
(158) 
 
(159) 
 
(160) 
(161) 
(149) 
 Liver Cancer 
 
Cancer 
 
Recurrence 
(early) 
Serum 
 
Serum 
N: 2000 
C: 5550 +/- 3110 
N: 5798 
C: 10759 
sE-cad above 8000 
(149) 
 
(174) 
 
(174) 
 Non-small cell 
lung 
Cancer  
 
Metastasis 
Serum 
 
Serum 
N: 1015 
C: 3455 
L2:  2487.8 
M2: 4422.2 
(166) 
 
(75) 
 Non-epithelial     
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Leimyosarcoma 
 
    Leukemia 
    Multiple    
       Myeloma 
Cancer 
 
Cancer 
Cancer 
 
Survival 
Serum 
 
Serum 
Serum 
 
Serum 
N: 2000 
C: 3280 +/- 720 
C: 2520 +/- 1000 
N: 622.9 
C: 3291.4 
s-Ecad above 3000 
(149) 
 
(149) 
(165) 
 
(74) 
 Ovarian Not 
significant 
 
 
Cancer 
 
 
 
Malignant 
ascites 
 
Present in 
ascites 
Serum 
 
 
 
Cyst  
 
 
 
Ascites 
 
 
Ascites 
Luteal cyst: 3677 
Dermoid tumor: 
2325 
Cystadenoma: 2200 
C: 2250 
Luteal cyst: 2035 
Dermoid tumor: ND 
Cystadenoma: 2000 
C:  14500 
N: 2061 +/-1968 
C: 12241 +/-5314 
 
C: 89.96 (ug/uL)/ug 
total protein  
(169) 
 
 
 
(169) 
 
 
 
(90) 
 
 
(92) 
 Prostate Cancer, 
metastasis 
Serum N: 6.270 ug/l 
L: 9.460 ug/l 
M: 27.490 ug/l 
(151) 
 Skin  
     Basal cell 
      
     Melanoma 
      
 
 
      
     Paget’s 
     Squamous   
         cell 
 
Not 
significant 
Cancer, 
rising S100 
Cancer, 
metastasis 
 
Invasion 
Not 
significant 
 
Serum 
 
Serum 
 
Serum 
 
 
Serum 
Serum 
 
N:  808 +/- 272 
C: 879 +/-485 
N: 3198 
C: 4975 
N: 808 +/- 272 
M: Values not 
reported 
C: Not reported 
C: 838 +/- 374 
 
(171) 
 
(85) 
 
(171) 
 
(171) 
(171) 
Non-cancer Acute 
pancreatitis 
Severe 
cases 
Serum N: 5181 +/- 1350 
D: 17780 +/- 7853 
(172) 
 Benign prostatic 
hyperplasia 
(BPH) 
BPH Serum N: 6.27 ug/l 
B: 7.26 ug/l 
(151) 
 Diabetes Not 
significant 
Not 
significant 
Serum 
 
Urine 
N: 2000 
D: 2330 +/- 1580 
N: 652.7 +/-87 
Diabetic:  721.9 +/-
93 
(149) 
 
(173) 
 Diabetic 
nephropathy 
(DN) 
Nephropath
y 
Urine N: 652.7 +/-87 
DN0:  721.9 +/-93 
DN1: 2751.5 +/- 164 
DN2: 5839.6 +/- 428 
(173) 
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 Inflammatory 
skin diseases 
     Psoriasis 
      
     Dermatitis 
 
 
Severe 
cases 
Severe 
cases 
 
 
Serum 
 
Serum 
 
 
Values not reported 
 
Values not reported 
(171) 
Infection HIV Viral load Plasma Values not reported (175) 
 Hepatitis Not 
significant 
Serum N: 2000 
D: 2340 +/- 520 
(149) 
Organ 
dysfunction 
Multi-organ Sepsis, 
organ 
dysfunction 
Serum N: 3280  
D: 6000 
(142) 
 Cholecystectom
y 
Inflammatio
n 
Serum Lap: 1850 +/- 250 
Open: 3110 +/- 330 
(143) 
N: normal, C: cancer, M: metastatic D: disease, R: recurrence, NR: No recurrence, 
PreOp: Preoperative . CRT: neoadjuvant chemoradiation therapy. L: localized, M: 
metastatic, Mult: Multiple, ND: not detected, DN0: diabetic, no nephropathy, DN1: 
diabetic nephropathy, microalbuminuria, DN2: diabetic nephropathy, macroalbuminuria, 
Lap: laparoscopic 1Value conversion from log (sE-cad ng/mL) to sE-cad ng/mL by 
Grabowska and Day. 2Observation reported by study’s author, but numbers generated 
by Grabowska and Day.  
 
Consequences of sE-cad presence 
Disruption of cell-cell interactions  
 The initial report by Wheelock et al demonstrated that sE-cad purified from 
MCF-7 cells was capable of disrupting cell-cell adhesion between mouse 
mammary tumor cells which were already growing in clusters (103) (Table 2-3).  
Later work demonstrated that treatment of ovarian cancer cell lines with a 
recombinant human ectodomain of E-cadherin fused to Fc, resulted in disruption 
of established cell junctions (90).  In re-aggregation assays, pancreatic cancer 
cells and MDCK cells treated with sE-cad immunodepleted media, were more 
efficient at re-aggregating than the cells which were re-aggregating in the 
presence of conditioned media with sE-cad present (78, 86). The presence of sE-
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cad can, therefore, not only disrupt established adherens junctions, but can also 
interfere with establishing adherence junctions in cell re-aggregation assays.  
sE-cad can also interfere with immune cell interactions by serving as a 
dummy ligand for KLRG1 and interfering with anti-viral functions. In HIV-infected 
peripheral blood mononuclear cells, the presence of a recombinant sE-cad 
interfered with the ability of T cells to secrete IFN-gamma in response to HIV-1 
Gag stimulation (150). Because KLRG1 on the CD8+ T cells bound sE-cad, the 
HIV infected CD4+ T cells were not targeted, resulting in an increase in survival 
of infected cells (150).  These data suggest that sE-cad is sufficient to disrupt 
cell-cell interactions which has implications for epithelial tissue stability and 
immune response.  
 
Migration and invasion 
 The presence of sE-cad can also induce cells to invade.  Ovarian cancer 
cells exposed to Fc-Ecadherin invade through a modified Boyden chamber (92). 
Similarly, pancreatic cancer and MDCK cells exposed to conditioned media 
containing sE-cad versus conditioned media immunodepleted of sE-cad, show 
much greater inclination toward migration in the presence of sE-cad (86, 176).  In 
the case of lung cancer, the presence of sE-cad in the conditioned media or in 
the form of an activating HAV peptide based on EC1 of E-cadherin, can induce 
MMP-2, -9, -14 transcription and activity as evaluate by zymography and 
increased invasion (177). sE-cad, therefore, can promote migration and invasion, 
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which may be due to its ability to induce additional metalloprotease activity to aid 
in these processes.   
 
Signaling, proliferation, and survival 
 There have been several studies that have examined the specific effects 
of sE-cad presence on cells. In breast cancer cells, endogenous sE-cad can be 
observed bound to HER2 and HER3 by immunoprecipitation (44). Stimulation 
with exogenous Fc-Ecadherin results in phosphorylation of HER2 and HER3, as 
well as downstream ERK signaling (44). Work by Najy et al also demonstrated 
that using a recombinant sE-cad resulted in a proliferative response in breast 
cancer cells, which was not mediated by full length E-cadherin since the line has 
a homozygous deletion for CDH1 (44). In our studies, sE-cad can also bind 
EGFR and signal downstream through ERK (unpublished observations).  
Conversely, in MDCK cells under serum free conditions, the anti-apoptotic 
signals provided by a myc-tagged sE-cad required E-cadherin expression (178). 
Treatment of these MDCK cells with a myc-tagged sE-cad resulted in signaling 
through EGFR and ERK (178). These studies suggest that sE-cad signaling is 
mediated by EGFR family members and, depending on the cellular context, may 
or may not be dependent on full length E-cadherin. Moreover, these studies 
suggest that sE-cad can stimulate proliferation and survival in non-transformed 
and transformed cells.  
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Discussion  
Although the accumulation of sE-cad was initially believed to be solely 
related to tumorigenesis, cell culture studies have revealed that the generation of 
sE-cad can be mediated by several mechanisms in a variety of pathological 
states. E-cadherin cleavage can be induced by pro-inflammatory cytokines, 
bacterial infection, serum withdrawal, apoptosis, and growth factors (44, 78, 80-
83, 85-87, 89-92, 104-109). To date, ADAMs (10 and 15), bacterial proteases 
(gingipains and BFT), cathepsins (B, L, S),  MMPs (2, 3, 7, 9, and 14), KLK7, and 
plasmin have all been implicated in the generation of sE-cad (44, 78, 80-83, 85-
87, 89-92, 104-109), but the study of E-cadherin processing is complicated by 
redundancy and the presence of proteolytic cascades.  
Proteolytic cascades, much like signal transduction cascades, allow for 
the amplification of a stimulus.  Mainly, when protease A is activated, it can 
activate protease B or C. The problem lies in determining whether it is protease A 
which is acting on the substrate or protease B or C, particularly when both 
protease belong to the same family, for example MMP-2,  9, and 13. The only 
true way to determine if a protease of interest cleaves a substrate is to use 
recombinant or purified proteins in an in vitro cleavage assay. This method 
requires the protease to be able to act upon the substrate without activating 
another mediator. The downside to this approach, however, is that it removes the 
protease and substrate from physiologically relevant situations, such as 
activation of the protease, presence of protease inhibitors, cell membrane 
interactions, as well as proteins associated with the substrate. Therefore, while 
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an in vitro cleavage assay will demonstrate cleavage in a best case scenario, it 
does not prove that the protease can act on the substrate in the context of a cell 
or biological system. The most thoroughly researched proteases, therefore, have 
extensive studies into their in vitro cleavage capabilities as well as 
complementing studies utilizing knockout animals, protease targeting shRNAs, 
as well as inhibitor studies.   
Assuming all reports of E-cadherin sheddases are accurate, there is an 
astounding amount of redundancy in the generation of sE-cad. Because cell 
culture evidence suggests that sE-cad can disrupt cell adhesion, immune 
response, as well as induce signaling and invasion (Table 3) and is associated 
with disease severity in patients (Table 2), sE-cad may be more than a symptom 
of protease disregulation and may actually be contributing to the progression or 
severity of disease.  Inhibiting E-cadherin cleavage, particularly in cancer, could 
be beneficial to patients and accomplished either by specific targeting of 
proteases implicated in a patient’s disease or using broad-spectrum inhibitors. 
Due to the poorly understood complex role of protease families such as the 
MMPs in early clinical trials, unintentional targeting of the entire zinc 
metalloprotease family (MMPs and ADAMs),  showed  little efficacy in cancer 
patients with advanced disease (124), and has prompted the development of 
more specific inhibitors for specific proteases and families, such as inhibitors for 
ADAM10 and 17 and the MMPs (31, 32, 124).  Although these specific inhibitors 
have not been designed for inhibiting E-cadherin cleavage per se, preventing the 
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generation of sE-cad could provide an additional, albeit unintended, benefit to 
patients undergoing cancer therapy.  
Regardless of the source of sE-cad, based on the published data, there 
are several observations that come to mind. First, sE-cad is present in a myriad 
of conditions from cancer to infection to organ failure, which suggests sE-cad will 
not be a singular biomarker for any specific disease or type. Instead, the use of 
sE-cad in a clinical setting would, most likely, be a prognostic marker and be 
used in conjunction with other biomarkers. Another issue with sE-cad as a 
biomarker is the ranges of sE-cad reported vary greatly for normal controls, and 
whether this has to do with race (159), healthy volunteers with unknown medical 
problems, or technical differences between laboratories executing the ELISA 
remains unclear. Should sE-cad be used as a biomarker for severity of disease, 
then the ELISA would have to be standardized on a national or international 
level, and part of that would have to entail analyzing different populations for 
serum sE-cad concentrations. Another approach would be to divide the sE-cad 
values by the normal control values, generating fold change values, but even this 
method produces considerable by overlap between various disease states 
(Figure 2-1). 
There are, however, several appealing aspects to using sE-cad in a 
clinical setting. For one, the majority of conditions use serum or urine samples, 
which are easy collection procedures versus needle biopsies, etc. Additionally, 
since sE-cad can be used to screen for many health issues, the ELISA could be 
run often in a diagnostic laboratory and contribute insights into disease severity, 
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progression, recurrence, therapeutic response, and prognosis. In disease 
severity, sE-cad can predict cases of severe acute pancreatitis after 12 hours of 
pain (172) as well as the levels of kidney dysfunction in diabetes patients (173). 
sE-cad levels can also predict disease progression and recurrence. On average, 
elevated sE-cad predicts gastric cancer recurrence an average 13 months before 
the recurrence (160), and higher levels of sE-cad in localized prostate cancer 
predict early recurrence (151). In melanoma, elevated levels of sE-cad in patients 
with low S100 values may also indicate patients likely to progress rapidly (85). 
Bladder, gastric, and liver cancer patients with high sE-cad levels are also more 
likely recur than patients with lower levels of sE-cad (152, 154, 160, 164). In 
terms of therapeutic response, NSCLC patients who have a partial response to 
Celecoxib and Erlotinib treatment show a decrease in sE-cad levels at 8 weeks 
(168). sE-cad is also an indicator of patient survival: esophageal squamous cell 
carcinoma, gastric cancer, and multiple myeloma patients with higher levels of 
sE-cad have a much shorter survival time than lower sE-cad patients (157, 161, 
165). These studies provide convincing evidence that sE-cad may provide 
additional information on disease severity, progression, recurrence, and 
therapeutic response which could aid in determining appropriate therapeutic 
intervention. 
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Table 2-3: Consequences of sE-cad presence 
 
Result System sE-cad source Mechanism (if 
known) 
Ref.  
Disruption of 
adherens 
junctions 
Ovarian cancer 
cell line 
Mouse mammary 
tumor cells 
Recombinant, Fc 
fusion 
 
Antibody affinity 
chromatography 
 (90) 
 
(103)
Disruption of 
anti-viral 
function 
Peripheral blood 
mononuclear 
cells from HIV 
patients 
Recombinant sE-
cad 
Abrogation of 
IFN-gamma 
response 
(175)
Disruption of 
cell 
aggregation 
Pancreatic 
cancer cell line 
Canine kidney 
cell line 
Immunodepletion 
 
 
Immunodepletion 
 (86) 
 
(176)
 
Invasion Ovarian cancer 
cell line 
Pancreatic 
cancer cell line 
Lung cancer cells 
 
Canine kidney 
cells 
Recombinant, Fc 
fusion 
 
Immunodepletion 
 
 
Immunodepletion; 
HAV peptide 
 
Immunodepletion 
 
 
 
 
Induction of 
MMP-2, 9, 14 
(92) 
 
(86) 
 
(177)
 
 
(176)
Proliferation Breast cancer 
cells 
Recombinant, Fc 
fusion 
HER2/HER3 
phosphorylation 
(44) 
Signaling Breast cancer 
cells 
 
Canine kidney 
cells  
 
Peripheral blood 
mononuclear cell 
from HIV patients 
Endogenous; 
Recombinant, Fc 
fusion 
Recombinant, 
myc tag 
 
Recombinant sE-
cad 
Binding to 
HER2/HER3 
ERK signaling 
pERK/pAKT via 
EGFR 
 
KLRG1 ligation 
(44) 
 
 
(178)
 
 
(175)
Survival Canine kidney 
cells  
Recombinant, 
myc tag 
EGFR signaling (178)
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Figure 2-1: Comparison of serum sE-cad levels among various malignancies. 
Malignancy concentrations of sE-cad were divided by the average normal concentrations 
within each study to provide fold change values.  
This work is an invited, peer-reviewed, and accepted review in Frontiers in 
Bioscience (citation unavailable at time of dissertation completion) 
 
55 
 
Chapter 3: EGF Promotes the Shedding of Soluble E-cadherin in an 
ADAM10-dependent Manner in Prostate Epithelial Cells 
 
Abstract 
During the progression of prostate cancer, the epithelial adhesion 
molecule (E)-cadherin can be lost from the cell surface by proteolytic processing, 
generating an extracellular 80kDa fragment referred to as soluble E-cadherin 
(sE-cad). Contrary to observations in cancer, the generation of sE-cad appears 
to correlate with ADAM10 activity in benign prostatic epithelium. The ADAM10-
specific inhibitors INCB008765 and proA10 inhibit the generation of sE-cad, as 
well as downstream signaling and cell proliferation. Addition of EGF or 
amphiregulin to these untransformed cell lines increases the amount of sE-cad 
shed into the conditioned media and sE-cad bound to EGFR. EGF-associated 
shedding appears to be mediated by ADAM10 as shRNA knockdown of ADAM10 
results in reduced shedding of sE-cad. To examine the physiologic consequence 
of sE-cad on benign prostatic epithelium, we treated BPH-1 and PrEC 
immortalized prostate epithelial cells with a sE-cad analog comprised of the 
human Fc domain of IgG1, fused to the extracellular domains of E-cadherin (Fc-
Ecad). The treatment of untransformed prostate epithelial cells with Fc-Ecad 
resulted in phosphorylation of EGFR and downstream signaling through ERK, 
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resulting in increased cell proliferation. Pre-treating BPH-1 and PrEC cells with 
cetuximab, a therapeutic monoclonal antibody against EGFR, decreased the 
ability of Fc-Ecad to induce EGFR phosphorylation, downstream signaling and 
proliferation. These data suggest that ADAM10-generated sE-cad may have a 
role in EGFR signaling independent of traditional EGFR ligands.  
 
Introduction 
 The human prostate, which is the size of a walnut, is a secretory organ 
that sits at the base of the bladder and is comprised of epithelial cell acini, 
separated by fibromuscular stroma (1).  Each acinus contains two compartments. 
The luminal compartment is comprised of AR positive, terminally differentiated, 
secretory luminal cells and terminally differentiating intermediate cells (2). The 
basal compartment contains proliferating, AR negative stem cells and transit 
amplifying cell, which can differentiate into terminally differentiating cells and 
finally luminal secretory cells (2). 
 Epithelial (E)-cadherin is a homophilic adhesion molecule, which is 
expressed at the baso-lateral membrane of epithelial tissues. At the adherens 
junction, adhesion requires E-cadherin dimerization with an adjacent homodimer 
and then further dimerization with a homodimer on an adjacent cell (65). 
Intracellular interactions of E-cadherin with beta-catenin, p120, and alpha catenin 
also support adhesion and stabilization of the adherens junction (72-75). E-
cadherin can be lost from the cell surface by promoter hypermethylation, gene 
deletion and mutation or proteolytic cleavage (77, 94). Previously, we have 
57 
 
observed that E-cadherin can be shed into the serum of benign prostatic 
hyperplasia and prostate cancer patients (93). One of the sheddases implicated 
in E-cadherin cleavage is ADAM10 (83, 84, 179).  
 ADAM10 is a member of the A Disintegrin And Metalloprotease (ADAM) 
family of zinc-dependent metalloproteases which is composed of 40 members, of 
which 12 members (including ADAM10) are catalytically active (26). Family 
members are characterized by five extracellular domains: prodomain, 
metalloprotease, disintegrin, cysteine-rich, and EGF-like. The multiple domains of 
ADAMs allow for a myriad of functions including proteolysis, integrin binding, and 
signal transduction (26). ADAM10 disregulation in inflammation and disease has 
made the protein’s catalytic domain a target for therapy (28, 31, 32). ADAM10 
has been implicated in E-cadherin cleavage in keratinocytes and gastric cancer 
cell lines (83, 84). In the prostate, membranous ADAM10 expression is high in 
BPH patient samples (36), and E-cadherin and ADAM10 co-localizes at the 
adherens junction (29). Because ADAM10 is predominantly a sheddase, which is 
known to cleave epidermal growth factor (EGF)-like ligands from the cell-surface, 
thus promoting epidermal growth factor receptor (EGFR) family signaling (27), 
we hypothesized that ADAM10-generated sE-cad impacts EGFR signaling by 
binding EGFR.   
 The EGFR family (EGFR/HER1/ErbB1, HER2/Neu/ErbB2, HER3/ErbB3, 
and HER4/ErbB4) is a prominent group of receptor tyrosine kinases. Comprised 
of an extracellular ligand binding domain, a transmembrane region, and a 
cytoplasmic tail containing the tyrosine kinase domain, these receptors play 
58 
 
critical roles in development and cancer (7). In the normal adult prostate, EGFR 
is expressed in basal cells and is localized in the lateral membrane junctions 
between the basal and luminal epithelium, while in BPH patients, EGFR staining 
expands to include moderate staining in a portion of luminal epithelium (14). 36% 
of BPH samples over-express EGFR (15), and increased levels of EGFR 
expression correlate with BHP grade (16). Some studies have even reported that 
by immunohistochemistry, BPH samples express more EGFR than prostate 
cancer samples (14, 17). These results suggest that EGFR may be a component 
of a regulatory pathway involved in aberrant epithelial hyperproliferation and 
disease in the prostate gland (16, 18).  
This is the first study demonstrating a functional interaction between sE-
cad and EGFR using benign prostatic epithelial models. This study also 
describes a novel and potentially important signaling axis involving sE-cad 
shedding and EGFR binding. Characterization of this signaling mechanism in the 
prostate would establish the sE-cad/EGFR axis as a potentially important 
mechanism of benign prostatic epithelial proliferation and possibly tumorigenesis. 
 
Materials and Methods 
Cell culture 
 Benign prostatic hyperplasia -1 (BPH-1) cells were generated by 
immortalizing human BPH cells with SV40 Large T antigen by Hayward et al 
(180). BPH-1 cells express cytokeratins consistent with prostatic luminal 
epithelial cells (positive for keratins 7, 8 18, 19; negative for the basal marker 
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keratin 14), but do not express AR protein or mRNA  (180). BPH-1 and prostate 
epithelial cells immortalized with large T antigen (PrEC) were cultured in RPMI 
1640 (Lonza) with 8% fetal bovine serum (HyClone) and 2mmol/L L-glutamine 
(Invitrogen) and Pen/Strep Amphotericin B (Pen/Strep: 10,000U/mL, Ampho 
25ug/mL; Bio Whittaker). Knockdown cells lines were additionally supplemented 
with 100ug/uL Zeocin. Cells were incubated at in cell culture dishes (BD Falcon) 
at 37°C and 5% CO2 in Forma Series II incubators (Thermo) with water pans 
(80% relative humidity achieved from evaporation).   
 
Cell treatments 
 Cells were pretreated with or treated in serum free (SF), phenol free RPMI 
(Gibco) and 2mmol/L L-glutamine (Invitrogen) and Pen/Strep Amphotericin B 
(Pen/Strep: 10,000U/mL, Ampho 25ug/mL; Bio Whittaker). Cells in Figure 3-4C,D 
were pre-treated with SF media for 1hr prior to abrogate autocrine EGFR 
signaling. Stock solutions of cell treatments: 10ng/uL EGF in PBS, 100ng/uL 
amphiregulin in PBS, 100ng/uL Fc-Ecadherin in PBS (R&D Systems), 100ng/uL 
Fc in PBS (R&D Systems); .05M 1,10 phenanthroline in methanol (Sigma); 
10mM INCB008765 in DMSO (Incyte); prodomain of ADAM10 (proA10) in 10% 
glycerol/PBS (Biozyme); 2mg/mL cetuximab (ImClone).  
 
Protein isolation, Western blotting and immunoprecipitation 
Cells were harvested by scraping and lysed as previously reported (24). 
Lysates were pelleted at 12,000rpm for 8 minutes at 4°C. The supernatants were 
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collected and quantitated using a Bradford assay (BioRad) with each sample 
being run in triplicate. For western blotting, equal amounts of protein were loaded 
into precast Tris-glycine SDS gels (Invitrogen) and transferred to nitrocellulose 
membranes (Millipore). Blots were blocked with 10% milk in TBST buffer, probed 
with antibodies diluted in 2.5% milk in TBST, and developed using ECL (Pierce; 
high sensitivity Millipore). Antibodies: E-cadherin (HECD-1, Invitrogen); EGFR 
(Ab-15, Neomarkers); ADAM10, tubulin (Millipore); phosphoERK, ERK, 
phosphoEGFR Y992, phosphoEGFR Y1068 (Cell Signaling). Signaling Western 
blots were quantitated using ImageJ (NIH) software, dividing phosphorylated by 
total amounts of protein, and normalized to untreated control lanes.  
For immunoprecipitation (IP), 500ug of protein were pre-cleared with 100ul 
of a 50/50 mix of Sepharose A beads (Invitrogen), 2.5% milk in TBST, and 1ug of 
control IgG for 30 minutes with end over end rotation. Lysates were then spun 
down for 3min at 8,000rpm and supernatants were transferred to new tubes 
containing 1ug of antibody and rotated end over end for 1hr at 4°C. Beads were 
then added and after another hour of rotation, IPs were spun down for 3min at 
8,000rpm and supernatants aspirated. Beads were washed three times in PBS 
and spun down. After final wash, the supernatant was removed and 35ul of 
βmercaptoethanol-containing loading buffer (50 mM Tris-HCl, pH 6.8; 2% SDS; 
10% Glycerol; 1% β-Mercaptoethanol;12.5 mM EDTA, 0.02 % Bromophenol 
Blue) was added to the beads. After 5min incubation at 100°C, IPs were again 
spun down and supernatants collected.  
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In vitro cleavage assay 
 The in vitro cleavage assay has been previously described (24). Briefly, 
immunopurified ADAM10 and E-cadherin were combined in Eppendorf tubes in 
PBS for 8hrs at 37°C. After incubation, 15ul of BME-containing loading buffer 
were added and samples were boiled for 5min, spun down, and supernatants 
collected.  
 
Proliferation assays 
 5,000 BPH-1 or 10,000 PrEC cells were plated in each well of a 96 well 
dish and allowed to grow for 24hrs. Cells were then washed and placed in serum 
free media and allowed to recover for 1hr. After 1hr in serum free media, cells 
were supplemented with treatments for 24hr to 48hrs in quadruplicate, at which 
point, CellTiter-Blue (Promega) was added and incubated for 1-4hrs. CellTiter 
Blue is a metabolic assay which determines cell viability by measuring the 
amount of resazurin dye converted to fluorescent resorufin by live cells 
(Promega). Plates were read on a Gemini Microplate Reader and normalized to 
serum-free control values at each time point. With the exception of Figure 3-6, 
which is a representative experiment analyzed using the Kruskal-Wallis and 
Dunn’s multiple comparison test, three independent experiments were combined, 
and statistical analysis was performed by Graphpad Prism utilizing the one-way 
ANOVA or paired t-test, as appropriate, and graphed as the mean with the 
standard error of the mean (SEM) for error bars. Values were considered 
significant if P < 0.05.  
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Generation of shA10 and shEGFP constructs 
Knockdown cell lines for BPH-1 and PrEC were generated by lentiviral 
transduction of short hairpin constructs for ADAM10 (forward: CAC CGC AGG 
TTC TAT CTG TGA GAA ACT CGA GTT TCT CAC AGA TAG AAC CTG C; 
reverse: AAA AGC AGG TTC TAT CTG TGA GAA ACT CGA GTT TCT CAC 
AGA TAG AAC CTG C) and EGFP (forward: CAC CGC CAC AAC GTC TATA 
TCA TGG CGA ACC ATG ATA TAG ACG TTG  TGG C, rev: AAA AGC CAC 
AAC GTC TAT ATC ATG GTT CGC CAT GAT ATA GAC GTT GTG GC) with 
Zeocin antibiotic resistance (Invitrogen). Lentivirus was generated by transfection 
(TfxTM-20, Promega) of HEK 293T cells with plasmids encoding lentiviral 
components (pFG12 containing shRNA, RCE, HCMV promoter, RSV Reverse 
transcriptase) and treating BPH-1 and PrEC cells with Millex-HV PVDF (.45um; 
Millipore)-filtered conditioned media from infected cells for 24hrs in the presence 
of polybrene (6ug/ml). After infection, culture media was supplemented with 
100ug/mL Zeocin. 
 
Results 
Proteolytic activation of ADAM10 correlates with generation of sE-cad in 
immortalized prostate epithelial cells.  
 Previously, we demonstrated that ADAM15-mediated shedding of sE-cad 
supported signaling through HER2 in human breast cancer cells (24). To 
determine whether this mechanism plays a role in normal prostate biology, we 
evaluated sE-cad in prostate epithelial cells immortalized with large T antigen 
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(PrEC) and benign prostatic hyperplasia cells (BPH-1). Under serum free 
conditions, sE-cad is generated in normal (PrEC) and hyperplastic (BPH-1) cells 
and shed into the media (Figure 3-1A). Unlike our previous studies, active 
ADAM15 does not correlate with sE-cad; instead presence of active ADAM10 
correlates with increased sE-cad, suggesting that ADAM10 plays a role in the 
cleavage event of E-cadherin in untransformed epithelial cells. Indeed, ADAM10 
immunopurified from BPH-1 cells is capable of cleaving E-cadherin to sE-cad in 
vitro, which can be inhibited by the addition of the ADAM10-specific inhibitors 
INCB008765 (INC, Incyte) and the prodomain of ADAM10 (BIO, Biozyme). The 
broad-spectrum metalloprotease inhibitor 1,10-phenanthroline (OPT) can also 
inhibit the generation of soluble E-cadherin (Figure 3-1B).  
 
Figure 3-1: Generation of sE-cad is associated with active ADAM10 expression in 
untransformed prostate epithelial cells. A. ADAM10 and ADAM15 profiles of BPH-1 
and PrEC cells treated with serum free medium for 24hrs. B. 8hr in vitro cleavage assay 
with ADAM10 and E-cadherin immunopurified from BPH-1 cells using ADAM10 specific 
inhibitors: Incyte inhibitor INCB008765 (INC), Biozyme ADAM10 prodomain (BIO), and 
broad spectrum metalloprotease inhibitor, 1,10-phenanthroline (OPT). CM: conditioned 
medium. WCL: whole cell lysate. sE-cad: soluble E-cadherin. fE-cad: Full length E-
cadherin. pA10: pro form of ADAM10. mA10: mature form of ADAM10. pA15 pro form of 
ADAM15. mA15: mature form of ADAM15. E-cad: E-cadherin. 1:1: Reconstituted 1 
aliquot E-cadherin with 1 unit ADAM10. 1:3: 1 unit E-cadherin with 3 units of ADAM10. 
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ADAM10 supports downstream signaling and proliferation in immortalized 
prostate epithelial cells.  
Because ADAM10 is a major sheddase of pro-forms of growth factors, we 
hypothesized that ADAM10 supports cell signaling and proliferation in prostate 
epithelial cells. Unsurprisingly, inhibition of ADAM10 with the small molecule 
inhibitors (INC) or its prodomain (BIO) in BPH-1 cells reduces signaling through 
ERK (Figure 3-2A). OPT treatment of BPH-1 cells inhibits all metalloproteases 
and completely inhibits pERK signaling, suggesting there are metalloproteases 
beyond ADAM10 than contribute to ERK signaling. Inhibition of ADAM10 by INC 
also reduces proliferation in BPH-1 cells as compared to vehicle (DMSO) 
controls (Figure 2B). ADAM10 knockdown in PrECs results in a dramatic loss of 
phosphoERK signaling as compared to scrambled control cells, which cannot be 
rescued by the addition of EGF alone (Figure 3-2C). Loss of ADAM10 also 
results in a decrease in PrEC proliferation (Figure 3-2C, D).  
 
sE-cad generation is promoted by EGF and mediated by ADAM10 
In untransformed cells, the shedding of sE-cad into conditioned media is 
promoted by the addition of EGF or amphiregulin (AREG), and increasing 
concentrations of these EGFR ligands results in increasing levels of sE-cad as 
compared to serum free controls (Figure 3-3A). Interestingly, EGF promotes 
more sE-cad generation than AREG. We theorized that this EGFR ligand 
promoted generation of sE-cad was mediated by ADAM10 and we generated 
knockdown cell lines to test this hypothesis. As expected, ADAM10 knockdown in 
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BPH-1 and PrEC cells reduced sE-cad generation (Figure 3-3B,C), suggesting 
that ADAM10 is responsible for E-cadherin cleavage in normal prostate 
epithelium.  
 
sE-cad binds EGFR in response to EGF and AREG 
 Based on our previous studies in breast cancer cells (24), we theorized 
that sE-cad could play a role in downstream signaling in normal prostate 
epithelium. In order to determine whether traditional ligands could compete with 
sE-cad for binding to EGFR, we treated BPH-1 and PrEC cells with the high-
affinity ligand EGF or the low affinity (181) ligand AREG. In the presence of these 
ligands, there is more sE-cad bound to the receptor as compared to untreated 
controls (Figure 3-4A,B), suggesting that EGFR ligands promote the interaction 
between EGFR and sE-cad in BPH-1 and PrEC cells. As in the conditioned 
media experiment, EGF treatment resulted in more sE-cad bound to EGFR than 
AREG treatment.  
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Figure 3-2: ADAM10 contributes to downstream signaling and proliferation in 
untransformed prostate epithelial cells. A. BPH-1 cells treated with ADAM10 specific 
inhibitors (1uM, 10uM INC;1uM BIO) for one hour show decreased pERK signaling, 
while the broad spectrum metalloprotease inhibitor OPT (1mM) abolishes all pERK 
signaling. B. BPH-1 cells treated with INC also show decreased proliferation at 24hrs 
compared to DMSO (vehicle). C. Knockdown of ADAM10 in PrEC correlates with a 
decrease in pERK signaling after 15min (without 1hr pre-treatment in serum-free 
medium), which could not be rescued by 5nM EGF treatment. D. ADAM10 knockdown 
also results in a decrease in proliferation at 24hrs. Western blots were quantitated using 
ImageJ and normalized to untreated cells. Changes in phosphorylated ERK (grey box) 
are represented as fold change over total ERK and normalized to the no treatment (NT) 
lanes. (D). Scram: non-specific shRNA control. shA10: shADAM10. pERK: 
phosphoERK. pERK/ERK: Fold change in ERK phosphorylation. 
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Figure 3-3: EGFR ligands promote the generation of sE-cadherin in an ADAM10-
dependent manner. A. Treatment of BPH-1 cells with increasing concentrations of EGF 
and amphiregulin (AREG) results in increased sE-cad in the conditioned medium at 24 
hours. The loss of ADAM10 by shRNA knockdown reduces the amount of sE-cad shed 
in response to 5nM EGF stimulation in BPH-1 (B) and PrEC (C) cells after 24hrs. CM: 
conditioned medium. WCL: whole cell lysate. NT: no treatment. 
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Fc-Ecadherin binds the extracellular domain of EGFR and induces receptor 
phosphorylation and downstream signaling.  
 In order to determine the effect of sE-cad on non-transformed epithelial 
cells, a commercially available sE-cad analog was used. Fc-Ecadherin (Fc-Ecad) 
is a chimeric protein of human IgG1 and the five extracellular domains of E-
cadherin, which is the same as sE-cad fused to human IgG1. Treatment of BPH-1 
and PrEC cells with 1nM Fc-Ecad results in the phosphorylation of EGFR at 
residues Y992 and Y1068, which correspond to activation of the ERK pathway 
(182, 183),  and results in downstream ERK signaling as compared to treatment 
with Fc alone (Figure 3-4C, D). The addition of Fc-Ecad to the untransformed cell 
lines also supports an increase in proliferation as compared to the Fc domain 
alone (Figure 3-5A, B). The increased proliferation observed with Fc-Ecad can 
partially rescue the proliferation defect observed in the BPH-1 and PrEC 
shADAM10 cell lines, suggesting that sE-cad signaling may be a component of 
ADAM10-mediated proliferation and signaling (Figure 3-6A, B).  
 Because this proliferative effect is mediated by EGFR, we theorized that 
pre-treatment of BPH-1 and PrEC cells with cetuximab, a therapeutic monoclonal 
antibody against the extracellular domain of EGFR, would prevent Fc-Ecad 
induced signaling. Indeed, pre-treatment of BPH-1 and PrEC cells with 
cetuximab is enough to reduce the amount of ERK signaling induced by Fc-Ecad 
and EGF (Figure 3-7A, B). Cetuximab pre-treatment is also sufficient to reduce 
the proliferative effect of Fc-Ecad for BPH-1 and PrEC cells (Figure 3-7C, D).  
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Figure 3-4: sE-cad can bind EGFR and result in downstream signaling. The addition 
of 5nM EGF and AREG (AR in figure due to space limitations) for 15 minutes also 
increases sE-cad association with EGFR in BPH-1 (A) and PrEC (B) cells. Treatment of 
BPH-1 cells (C) and PrEC (D) cells with 1nM Fc-Ecad for 15 minutes results in increased 
phosphorylation of EGFR at tyrosine residues 992 (Y992), 1068 (Y1068) and increased 
phosphorylation of ERK, as compared to untreated and 1nM Fc domain (Fc) treated 
cells. Western blots were quantitated using ImageJ and normalized to untreated cells. 
Changes in phosphorylated EGFR or phosphorylated ERK (grey boxes) are represented 
as fold change over total EGFR or ERK and normalized to the no treatment (NT) lanes. 
fE-cad: full length E-cadherin. sE-cad: soluble E-cadherin. Y992/EGFR: Fold change 
tyrosine residue 992 phosphorylation. Y1068/EGFR: Fold change tyrosine residue 1068 
phosphorylation. pERK/ERK: Fold change in ERK phosphorylation. 
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Figure 3-5: Fc-Ecad induces proliferation. BPH-1 cells (A) and PrEC (B) cells respond 
proliferatively to Fc-Ecad as compared to Fc domain alone. Values were considered 
significant if p<0.05. NS: not significant. *: p< 0.05. **: p < 0.01. 
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Figure 3-6: Fc-Ecad can partially rescue the proliferation defect in shADAM10 
cells. Loss of ADAM10 in BPH-1 (A) or PrEC (B) cells results in decreased proliferation 
as compared to scramble control cells. 1nM Fc-Ecad stimulation of the BPH-1 shA10 (A) 
and PrEC shA10 (B) cells results in partial rescue of this proliferation defect. Values 
were considered significant if p<0.05. *: p< 0.05. 
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Figure 3-7: Cetuximab inhibits signaling and proliferation in response to Fc-Ecad.  
BPH-1 (A) and PrEC (B) cells pre-treated with 10nM cetuximab (Ct) for one hour show 
inhibition of phosphoERK signaling in response to 5nM EGF (E) and 5nM Fc-Ecad 
(FcE). BPH-1 (C) and PrEC (D) Fc-Ecad induced-cell proliferation is inhibited by 
cetuximab at 10nM and 20nM concentrations, respectively. Asterisks denote significant 
difference between Fc-Ecad and Fc-Ecad+Cetuximab treated cells NT: no treatment. *: 
p< 0.05. **: p < 0.01. *** p < 0.001.  
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Discussion 
 E-cadherin plays critical roles in epithelial cell maintenance, and its loss 
from the cell surface during tumor progression has been well documented. 
Previous work in the lab has focused on the accumulated 80kDa fragment known 
as sE-cad and the metalloprotease responsible during breast and prostate 
cancer progression (43, 93, 170). While ADAM15 appears to be the predominant 
metalloprotease responsible for sE-cad shedding in breast and prostate cancer, it 
may not play a significant role in normal prostate biology.  
 This work has demonstrated that ADAM10 plays a significant role in the 
proliferation of prostate epithelium, and that by blocking ADAM10 activity or 
reducing its expression results in decreased cell signaling and division, which is 
in accordance with earlier studies by Kasina et al (30). We also demonstrated 
that non-transformed prostate epithelial cells can be induced to generate sE-cad 
by the addition of EGF or AREG and that this process is dependent upon 
ADAM10. While the cleavage of E-cadherin by ADAM10 is not a novel finding 
(84, 179), this is first report of it in prostate epithelial cells.  
Additionally, the promotion of sE-cad generation by EGF suggests that 
shedding of E-cadherin may contribute to epithelial to mesenchymal transition 
(EMT) in pathologies such as BPH and prostate cancer. The loss of differentiated 
epithelial phenotypes and the acquisition of motility and invasiveness which are 
the hallmarks of EMT, play critical roles in tumor progression (96, 184). In 
prostate cancer, EMT drives bone metastasis (97), and emerging evidence 
suggests EMT may play a role in BPH as well (99). In BPH, there is a substantial 
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increase in the amount of stroma surrounding the epithelium (2), and work by 
Alonso-Magdalena et al suggested that in human samples, the disease did not 
arise from stromal proliferation, but from mesenchymal cells derived from the 
epithelium, implicating the process of EMT (99). This process can be 
recapitulated in vitro, where BPH-1 cells can be induced to undergo EMT by 
TGF-β1 (185). Our observations of elevated levels of sE-cad in BPH patients 
(93), coupled with high expression of ADAM10 (36) and EGFR (14-16, 18), 
suggests that the cleavage of E-cadherin induced by an EMT activator such as 
EGF (186) may contribute to EMT progression. Furthermore, the emerging 
evidence for the role of inflammation in BPH (2), coupled with the ability of 
proinflammatory cytokines to induce ADAM10 activity (84), suggests other 
factors could induce sE-cad cleavage as well.  
While previous publications from our group have demonstrated that sE-
cad can bind to HER2 and HER3 (44), and other studies have reported the 
interaction of full length E-cadherin and EGFR extracellular domains (70), this is 
the first report of the sE-cad bound to EGFR in a prostate cell line model. Our 
studies have also demonstrated that Fc-Ecad can induce phosphorylation of 
EGFR, support downstream signaling and culminate in increased proliferation. 
These experiments suggest that sE-cad binding to EGFR may play a role in 
aberrant proliferation of prostate epithelial cells and EMT as described in BPH 
(Figure 3-8). Other studies have demonstrated that sE-cad can disrupt cell 
adhesion, anti-viral function, cell aggregation (77, 78, 86, 90, 175), and support 
invasion, migration, proliferation, and survival (44, 78, 86, 92, 175, 177, 178). 
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Taken together, these results suggest that EGF promoted-ADAM10 cleavage of 
E-cadherin may contribute to proliferative disorders by allowing sE-cad to bind 
EGFR and alter downstream signaling and proliferation in prostate epithelium.  
 
 
Figure 3-8: The sE-cad/EGFR signaling axis. EGF promotes the ADAM10-dependent 
cleavage of E-cadherin, disrupting the adherens junction and generating sE-cad, which 
may promote EMT. sE-cad can then bind EGFR, which can result in downstream 
signaling and may promote further promote EMT.  
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Chapter 4: Generation of a Prostate Specific ADAM10 Knockout Mouse 
 
Abstract 
 ADAM10 and 15 disintegrins play important regulatory roles in prostate 
biology and disease. In order to better characterize the role of ADAM10 in normal 
prostate biology, we generated prostate specific knockout mice utilizing the 
probasin (Pb) driven Cre.  Adam10 loxP/loxP Pb-Cre mice are viable and reproduce 
normally, although early analysis indicates an epithelial hyperplasia into the 
luminal space, which warrants further investigation. The knockout cell lines are 
true knockouts as they express no ADAM10 and are currently being 
characterized in terms of E-cadherin shedding.  
 
Introduction 
 The A Disintegrin and Metalloprotease (ADAM) family of zinc-dependent 
metalloproteases is composed of 40 members characterized by five extracellular 
domains: prodomain, metalloprotease, disintegrin, cysteine-rich, and EGF-like. 
The multiple domains of ADAMs allow for a myriad of functions including 
proteolysis, integrin binding, and signal transduction (26). Our interest in the 
disintegrin family arose from the observation that ADAM15 is over-expressed in 
prostate cancer and is critical in driving cancer progression (39, 43), while our 
studies in untransformed prostate biology indicated a role for ADAM10 in BPH.  
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In order to better characterize the roles of ADAM10 and 15 in normal 
prostate biology, we turned to mouse prostate knockout cell lines. Adam15-/- mice 
are viable (56) and prostate epithelial cells lines could be isolated from mature 
adult males. ADAM10-/- mice, however, are embryonic lethal at embryonic day 
9.5, with defective central nervous system and heart developments, somite 
formation and vasculogenesis, which is a phenocopy of the Notch-/- mouse (55). 
Generation of prostate specific Adam10 knockout mouse utilized an Adam10 
loxP/loxP mouse (60) crossed with a mouse carrying a Cre recombinase driven by 
the rat probasin (Pb-Cre) (187). The activation of Pb-Cre by androgens at sexual 
maturity of the male mice at six weeks results in recombination within the lobes 
by 8 weeks, with recombination efficiency varying by lobe (187). The generation 
of Cre recombinase results in the excision of Adam10 exon 9, creating a 
frameshift mutation which interrupts translation (60) (Figure 4-1A).  
Like the human prostate gland, the mouse prostate is comprised for AR 
positive luminal cells and AR negative basal cells which can differentiate into 
luminal cells (2). Due to the AR-dependence of the Pb-Cre promoter, 
recombination should only occur in the differentiated luminal cells. Studies of the 
Adam10 loxP/loxP Pb-Cre mouse, therefore, focus on the role of ADAM10 in luminal 
cells.  
We report that Adam10 loxP/loxP Pb-Cre mice are viable and reproductively 
sound, although there does appear to be an unexpected hyperplasia associated 
with loss of ADAM10, the cause of which has not been determined. Additionally, 
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the prostate epithelial cell lines from Adam10 loxP/loxP Pb-Cre mice are viable and 
do not express ADAM10 protein.  
 
Materials and Methods 
Generation of the tissue specific ADAM10 knockout mouse 
 Female Adam10 +/loxP (provided by Dr. Peter Dempsey) mice on a 
congenic C57BL/6 background were crossed with male C57BL/6 Pb-Cre mice 
(available at Charles River, provided by June Wilke and Dr. Evan Keller). 
Resulting Adam10 +/loxP Pb-Cre male mice were crossed with female Adam10 
+/loxP mice in order to generate breeding pairs with male Adam10 loxP/loxP Pb-Cre 
males and female Adam10 loxP/loxP mice.  
 
Genotyping 
 Tail tips of four week old mice were frozen overnight upon removal. The 
following day, each tail was incubated at 55°C in a mix of 500ul of Nuclei Lysis 
Solution (Promega) and 100ul .5M EDTA with vortexing every hour. After three 
hours, 200ul of Protein Precipitation Solution (Promega) was added and tubes 
were incubated on ice for 10 minutes (min) prior to a 10 min spin at 4°C of 
16,000 relative centrifuge units (rcf; Eppendorf centrifuge 5415 R). The 
supernatants were transferred to new tubes and the spin step was repeated. The 
supernatants were then transferred into new tubes containing 600ul isopropanol 
and mixed until threads of DNA appeared. Tubes were spun down for 2 min at 
16,000rcf at 25°C, supernatants were removed, and pellets were washed with 
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70% ethanol, and spun as before. Finally, the ethanol was aspirated off and 
pellets were allowed to briefly air dry before reconstitution in DNase and RNase 
free water.  
 2ul of each DNA sample was then combined with 15ul of Platinum PCR 
mix (Invitrogen), and 2ul of primer mix (Invitrogen), and were then subjected to 
the following PCR protocols: 
Cre: Step 1: 94°C x 2min. Step 2: 94°C x 1min. Step 3: 60°C x 1min. Step 
4: 72°C x 1min. Step 5: Steps 2-4 x 35 times. Step 6: 72°C x 9min. Step 7: hold 
4°C. Primers: Cre 3’: ACC GTC AGT ACG TGA GAT ATC TT; Cre 5’: ACC TGA 
AGA TGT TCG CGA TTA TCT 
 ADAM10: Step 1: 95°C x 5min. Step 2: 95°C x 20sec. Step 3: 55°C x 
1min. Step 4: 72°C x 2min. Step 5: Steps 2-4 x 35 times. Step 6: 72°C x 10min. 
Step 7: hold 4°C. Primers: Exon 9: GTT GGA CAT AAC TTT GGA TCT CC. 
Intron 9: CGT ATC TCA AAA CTA CCC TCC C. Neo reverse: CAA GTT CTA 
ATT CCA TCA GAA GC. Intron 8: CAG TGT AAA TGT GAA CTC ACC C.  
 PCR samples were then run out on a 1.5% agarose gel for 1hr at 90V. 
The band sizes and corresponding genotypes are as follows: Exon 9/ Neo 
reverse: 327bp for loxP allele. Exon 9/Intron 9: 414bp Neo, 235 wild-type. Intron 
8/Intron 9: 217bp Cre recombined, 955bp Neo unrecombined, 715bp wild type.  
 
Processing of animal tissues 
 Experimental (Adam10 loxP/loxP Pb-Cre ) and control (Adam10 loxP/loxP) male 
mice were euthanized by approved UCCUCA protocols. Anterior, ventral, and 
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dorsolateral prostate lobes were removed from mice ages 12-24 weeks and 
processed as follows. For protein analysis: prostatic tissue was removed and 
flash frozen in liquid nitrogen then homogenized with a mortar and pestle and 
lysed in RIPA buffer and inhibitors as previously described (3). For DNA: 
samples were flash frozen in liquid nitrogen and DNA extraction followed the 
above genotyping protocol.  
For frozen sections: Lobes were removed and stained with tissue marking 
dyes (Cancer Diagnostics, Inc) then fixed in 4% paraformaldehyde in .1M PBS 
on ice for 3hrs. Tissues were then washed 4-6 times in PBS over 4hrs at 4°C, 
and then placed in 30% sucrose overnight. In the morning, tissues were 
transferred to cassettes sitting on dry ice and covered with OCT (Tissue Tek). 
Once the mounting media firmed, cassettes were transferred to the -20°C freezer 
until sectioning.  
For paraffin embedded sections: Prostate lobes were extracted and 
placed on PBS-dampened tissue paper and then dyed (red: anterior, blue: 
ventral, green: dorsolateral; Cancer Diagnostics, Inc). Tissue paper was folded 
around the tissues, and closed within a cassette. Cassettes were fixed overnight 
in 10% buffered formalin at 4°C, and then transferred to 70% ethanol for one 
hour before processing by the histology lab. Paraffin embedding, frozen and 
paraffin-embedded sectioning, hematoxylin and eosin (H&E) and 
immunohistochemistry was performed by the University of Michigan Cancer 
Center Research Histology & Immunoperoxidase Laboratory. Antibody: mouse 
ADAM10 (Millipore) diluted 1:100, incubated 1hr at room temperature. 
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Generation of mouse prostate epithelial cell lines 
Prostates were extracted from male mice of 18 weeks. Prostate explants 
were diced in Primaria surface modified polystyrene plates (Falcon) and a drop of 
primary mouse cell media was added. Primary mouse culture media: 1:1 
RPMI1640/Ham’s F12 (Lonza, Gibco) with: 2mmol/L L-glutamine (Invitrogen); 
Pen/Strep Amphotericin B (Pen/Strep: 10,000U/mL, Ampho 25ug/mL; Bio 
Whittaker); 10mg/L Bovine Pituitary Extract (Sigma); .5mg/mL Cholera Toxin 
(Sigma); 5uM Dexamethasone (Sigma); Insulin, Transferin, Selenious Acid (ITS) 
Premix (Collaborative Res 5ug/mL Insulin, 5ug/mL Transferrin and 5ng/mL 
Selenious Acid);  10ng/mL EGF (Collaborative Res.); 5ug/L Insulin-like growth 
factor-1 (IGF-1) (Collaborative Res.). Cells were allowed to grow out from 
explants and passed in mouse media for 5 passages, at which point the 
spontaneously immortalized mouse prostate cells were transferred to normal 
plates and RPMI 1640 (Lonza) with 8% fetal bovine serum (HyClone) and 
2mmol/L L-glutamine (Invitrogen) and Pen/Strep Amphotericin B (Pen/Strep: 
10,000U/mL, Ampho 25ug/mL; Bio Whittaker).  
 
Protein isolation, Western blotting and immunoprecipitation 
Cells were harvested by scraping and lysed as previously reported (3). 
Lysates were pelleted at 12,000rpm for 8 minutes at 4°C. The supernatants were 
collected and quantitated using a Bradford assay (BioRad) with each sample 
being run in triplicate. For western blotting, equal amounts of protein were loaded 
into precast Tris-glycine SDS gels (Invitrogen) and transferred to nitrocellulose 
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membranes (Millipore). Blots were blocked with 10% milk in TBST buffer, probed 
with antibodies diluted in 2.5% milk in TBST with overnight incubation and 
developed using ECL (Pierce; high sensitivity Millipore). Antibodies: ADAM10 
(1:1000, Millipore), actin (1:2000, Sigma).  
 
Results: 
Prostate-specific ADAM10 knockout mouse phenotype 
Adam10 loxP/loxP Pb-Cre mice are viable, reproduce normally, and develop 
prostates. We observed tissue specific recombination in all three lobes of the 
prostate (Figure 4-1B). Preliminary analysis of anterior prostate morphology of 
Adam10 loxP/loxP Pb-Cre mice at 28 weeks indicated some hyperplasia of the 
luminal compartment and changes in gross anatomical structure (Figure 4-2). In 
order to address whether this change was due to loss of ADAM10, we stained 
tissues with an anti-mouse ADAM10 antibody (Figure 4-3). Preliminary staining 
showed that the littermate control males had uniform expression of ADAM10 in 
luminal cells at the cell membrane. Surprisingly, ADAM10loxP/loxP Pb-Cre mice had 
areas of intense membranous staining and areas of diffuse cytoplasmic staining.   
The unexpected presence of ADAM10 in these 28 week old mice, when 
we had observed recombination at 18 weeks, suggested that expression of 
ADAM10 on the luminal cell membrane may be critical for gland organization and 
loss of ADAM10 may result in luminal cell death. We postulated that these areas 
of increased proliferation into the luminal space and persistent ADAM10 staining 
could be differentiating basal cells which had not yet begun to express AR. 
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Conversely, these areas could represent a loss of guidance for differentiating 
basal cells, which could require ADAM10-mediated signaling for proper location 
and differentiation. Recent studies in dermatology have demonstrated a 
thickening of the epidermis in response to cytokeratin-5 driven ADAM10 ablation, 
which was due to basal cell hyperproliferation and disturbed differentiation (58), 
so it is possible we are observing a similar phenotype.  
In an attempt to better characterize this phenotype, we generated a cohort 
of two experimental and two control animals aged 12-24 weeks at two week 
increments for future studies. The samples collection is complete; all tissues are 
embedded and awaiting further analysis. Future studies will examine the loss of 
ADAM10 expression over time, as well as examine rates of apoptosis and 
differentiation markers.  
 
ADAM10 knockout prostate epithelial cell lines 
 Establishment of prostate epithelial cell cultures took approximately one 
year. We generated a cell line from the anterior prostate of a littermate control 
(A10 Ant +/+) and two cell lines from the anterior (A10 Ant-/-) and ventral (Vent 
A10 -/-) prostates of an Adam10 loxP/loxP Pb-Cre mouse. Knockout cells are true 
knockouts with no ADAM10 expression (Figure 4-4). Future studies of these cell 
lines will include characterization of differentiation markers, E-cadherin shedding, 
and proliferation rates.  
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Figure 4-1: Generation of ADAM10 loxP/loxP Pb-Cre mice. A. Exon 9 of the ADAM10 
loxP/loxP  mouse is targeted for excision by Cre, which results in a frameshift mutation and 
loss of protein expression (6). Figure adapted from Gibb et al (6). B. Genotyping of 18 
week old mouse prostates. ADAM10 loxP/loxP  Pb-Cre mice have Cre expression and 
recombine the ADAM10 loxP/loxP  to the knockout allele. Wild-type controls do not express 
Cre and retain the ADAM10 loxP/loxP  allele.  
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Figure 4-2: Morphology of 28 week old mouse prostates. The anterior prostate of 
experimental and control animals, aged 28 weeks, was stained with H&E. Red staining 
on sections is tissue dye for lobe identification purposes.  
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Figure 4-3: ADAM10 staining of 28 week old mouse prostates. Serial sections from 
Figure 2 with immunohistochemistry for ADAM10 performed. Red stain is tissue dye for 
lobe identification purposes.  
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Figure 4-4: Mouse prostate epithelial cells derived from 18 week old mice. 
Comparison of prostate epithelial cells derived from ADAM10 loxP/loxP  anterior prostate, 
anterior and ventral ADAM10 loxP/loxP  Pb-Cre prostates, and prostate tissue from an 
ADAM15-/-mouse. msPrEC: mouse prostate epithelial cells. pA10: ADAM10 pro form. 
mA10: mature ADAM10.  
 
 
Discussion: 
 We have generated a prostate-specific Adam10-/- mouse (ADAM10 loxP/loxP  
Pb-Cre), which has lost Adam10 expression in all lobes of the prostate and 
allowed for the establishment of knockout prostate epithelial cells. Our 
preliminary data indicates a role for ADAM10 in prostate tissue homeostasis. 
Loss of ADAM10 appears to initiate a hyperproliferative response, which results 
in cell proliferation into the luminal space. This process appears to be coupled 
with basal cell differentiation since areas of strong ADAM10 expression persist in 
experimental prostates. In order to better characterize this phenotype, we have 
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also generated a cohort of control and experimental prostatic tissue samples of 
mouse ages 12-24 weeks and embedded them in paraffin blocks. These samples 
will serve in determining the timeline for ADAM10 loss in luminal cells and 
expression by differentiating cells. It will also allow for examination of 
inflammatory mediators and lineage markers which could determine whether the 
hyperproliferation is due to wound healing or misguided differentiation.  
Based on our early observations, coupled with our data in ADAM10 
function in BPH and data of others in cancer, we believe it would be interesting to 
breed our prostate-knockouts to models of BPH and cancer. Unfortunately, 
studies of BPH in the laboratory setting are complicated by a lack of good 
models. Rodents do not develop spontaneous BPH, but treatments with 
androgens and estrogens, as well as LXR knockout and over-expression of 
prolactin or murine IL-8, can induce prostate hyperproliferation with stromal 
involvement (1). We could quite easily treat our mice with androgen and estrogen 
or breed them onto one of these backgrounds and examine the consequences 
on BPH. Conversely, other groups have focused on xenografting cell lines either 
orthotopically or in the sub-renal capsule with mouse urogenital sinus as a model 
of BPH (188), which we could pursue with our ADAM10-/- cell lines as well.   
In terms of cancer, there are many well-established models of prostate 
cancer in mice and it would be interesting to examine the effect of ADAM10 loss 
on tumor progression in the TRAMP mouse which relies on probasin-driven over-
expression of the SV40 oncogene. Because castration of TRAMP mice with 
established tumors results in androgen independent disease (189), it would be 
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interesting to examine if ADAM10 plays a role in tumor development in this 
model. Other studies could also examine ADAM10 involvement in the tumor 
progression of Pten, Akt-1, and HER2 transgenic prostate cancer models (189).  
Beyond further characterization of the Adam10 loxP/loxP Pb-Cre mice and 
examining the role of ADAM10 in mouse models of BPH and cancer, the 
established cell lines will also be further analyzed. The prostate epithelial cell 
lines established from an Adam10 loxP/loxP Pb-Cre mouse are viable and do not 
express ADAM10. Studies are currently underway to better characterize these 
cells in terms of E-cadherin cleavage. Also, in conjunction with previously 
generated Adam15-/- prostate epithelial cell lines, the ADAM10-/- prostate cell 
lines will be tremendously useful in determining what roles ADAM10 and 
ADAM15 play in normal biology. Because ADAM10 and ADAM15 share some 
substrates, knockout cell lines will aid in determining the specificity of our future 
therapeutics. For example, highly specific ADAM15 inhibitors should have no 
effect on the shedding profile of ADAM15-/- cells. Additionally, the knockout cells 
will provide additional information on the requirements for ADAM10 and ADAM15 
interaction and inhibition (covered in Chapter 5).
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Chapter 5: Characterizing the Interactions Between ADAM10 and ADAM15 
 
Abstract 
 The disintegrins ADAM10 and ADAM15 have both been implicated in 
prostate cancer progression and E-cadherin cleavage. Because of our interest in 
targeting ADAM15 in prostate cancer, we set out to characterize ADAM domains 
in terms of E-cadherin cleavage, investigate ADAM10 inhibitors for ADAM15 
inhibition, and to better characterize the interaction between ADAM10 and 
ADAM15. Our preliminary studies suggest that over-expression of ADAM15 in 
BPH-1 cells increases sE-cad generation but this process is EGF-independent. 
For ADAM15, the EGF-like domain appears to be critical for substrate specificity, 
and expression of an EGF-like mutant reduces sE-cad generation. We have also 
observed the ADAM10 inhibitor INCB08765 can inhibit ADAM15 activity during 
the in vitro and CD23 peptide cleavage assay and that ADAM15 and ADAM10 
co-immunoprecipitate as a catalytically active unit. These preliminary studies 
further confirm our observation that EGF-promoted generation of sE-cad is an 
ADAM10-driven process, demonstrate a novel role for the EGF-like domain, and 
present an interesting observation of ADAM10 and 15 functional interactions.  
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Introduction  
The human A Disintegrin and Metalloprotease (ADAM) family of 
disintegrins is comprised of zinc-dependent metalloproteases which contains 25 
members, of which only 13 members (including ADAM10 and 15) are catalytically 
active (26). Family members are characterized by five extracellular domains: 
prodomain, metalloprotease, disintegrin, cysteine-rich, and EGF-like. The 
multiple domains of ADAMs allow for a myriad of functions including proteolysis, 
integrin binding, and signal transduction which have been implicated in 
development and disease (26).  
Previously, Kuefer et al reported that ADAM15 is significantly over-
expressed in breast, prostate, ovarian, gastric, and lung cancer (39). Further 
studies have implicated ADAM15 in prostate cancer progression and breast 
cancer proliferation (39, 43, 44), and ADAM15 catalytic and disintegrin activity 
has also been reported to mediate inflammation (52, 53) and platelet aggregation 
(54). The multidomain structure of ADAM15 allows its unique RGD sequence in 
the disintegrin domain to interact with alphavbeta3, alpha5beta1, and alpha9beta1 
(45-47) to support adhesion, while its metalloprotease domain can cleave 
substrates such as CD23, pro-amphiregulin, pro-HB-EGF, E-cadherin, N-
cadherin, and ADAM10 (38, 40-44).  
ADAM10 is predominantly a sheddase, which is known to shed epidermal 
growth factor (EGF)-like ligands from the cell-surface and promote epidermal 
growth factor receptor (EGFR) family member signaling (27) and plays a critical 
role in the regulated intramembrane proteolysis (RIP) of Notch, CD44, and Fas 
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ligand, whereby sequential processing of the pro-form by ADAM10 and gamma-
secretase allows the intramembrane fragment to enter the nucleus and induce 
transcription (28). ADAM10 itself can undergo RIPping mediated by ADAM15 
(38), and this process may play a role in prostate cancer where ADAM10 staining 
expands to the nucleus in patient samples and, in vitro, is promoted by DHT (36). 
Interestingly, the soluble ADAM10 retains its catalytic activity to some degree 
(38), suggesting it may continue to act on substrates even after processing. 
Cleavage of ADAM10 by ADAM15 is particularly interesting because ADAM10 is 
the other disintegrin implicated in epithelial (E)-cadherin cleavage (84).  
E-cadherin is a homophilic, calcium-dependent, adhesion protein, which is 
expressed at adherens junctions between epithelial cells and contains an 
extracellular region comprised of 5 domain repeats, each domain containing a 
set of seven beta-sheets arranged in an immunoglobulin fold (64). Adhesion 
depends on dimerization between E-cadherin molecules on the same cell, which 
interacts with an E-cadherin homodimer on a neighboring cell via cadherin repeat 
1 (EC1) (65). E-cadherin can also interact with receptor tyrosine kinases, such as 
EGFR, and this depends upon the extracellular domain of E-cadherin (70). 
Cleavage of E-cadherin to soluble E-cadherin (sE-cad) not only disrupts 
adherens junctions (77), but it also allows sE-cad to bind members of the EGFR 
family and result in downstream signaling (44) (Chapter 3).  
The EGFR family is comprised of four transmembrane tyrosine kinase 
members: EGFR (ErbB1, HER1), HER2 (ErbB2, Neu), HER3 (ErbB3), and HER4 
(ErbB4) (7). EGF-like ligand binding to a single receptor allows for dimerization 
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with an adjacent ligand bound receptor and transautophosphorylation of the 
kinase domain, which allows for the docking of Src homology (SH2) domain or 
phosphotyrosine binding (PTB) containing proteins, which mediate further 
downstream signaling events (8, 9). In prostate cancer, EGFR staining is strongly 
associated with castration resistant prostate cancer (CRPC) and EGFR family 
member signaling may contribute to androgen independence (19). HER2 
expression in prostate cancer has been associated with androgen-independent 
AR signaling, poor survival in CRPC, and promotes prostate cancer cell growth in 
bone (22-24).  
Because ADAM10 and ADAM15 are both over-expressed in prostate 
cancer and support EGFR family member signaling, we and others have 
determined that they are good candidates for targeted therapy. Frequent 
disregulation of ADAM10 in inflammation and disease has made the protein’s 
catalytic domain a target for therapy and specific ADAM10 inhibitors are available 
today (31-34). On the other hand, ADAM15 targeting is still nascent, but work on 
generating ADAM15-specific inhibitors is underway. The purpose of these 
studies, therefore, was to determine the domain requirements for E-cadherin 
cleavage by ADAM15, investigate cross-reactivity of available therapeutics for 
ADAM10 on ADAM15, and to better characterize the interaction between 
ADAM10 and 15.  
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Methods and Materials 
Cell culture 
 Benign prostatic hyperplasia -1 (BPH-1), LNCaP, and PC-3 cells were 
cultured in RPMI 1640 (Lonza) with 8% fetal bovine serum (HyClone) and 
2mmol/L L-glutamine (Invitrogen) and Pen/Strep Amphotericin B (Pen/Strep: 
10,000U/mL, Ampho 25ug/mL; Bio Whittaker). ADAM15 over-expressing cell 
lines generated by Dr. Abdo Najy (LNCaP, PC-3) (43, 44) and Dr. Neali Lucas 
(BPH-1) were additionally supplemented with 800mg/mL G418. LNCaP ADAM15 
knockdown cells were generated with previously reported constructs (43). Cells 
were incubated at 37°C.  
 
Cell treatments 
 Cells were pretreated with or treated in serum free, phenol free RPMI 
(Gibco). Stock solutions of cell treatments: 10ng/uL EGF in PBS (R&D Systems); 
10mM INCB008765 in DMSO, 10mM INCB012881in DMSO (Incyte); prodomain 
of ADAM10 in 10% glycerol/PBS (Biozyme). 
 
Protein isolation, Western blotting and immunoprecipitation 
Cells were harvested by scraping and lysed as previously reported (43). 
Lysates were pelleted at 12,000rpm for 8 minutes at 4°C. The supernatants were 
collected and quantitated using a Bradford assay with each sample being run in 
triplicate. For western blotting, equal amounts of protein were loaded into precast 
Tris-glycine SDS gels (Invitrogen) and transferred to nitrocellulose membranes 
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(Millipore). Blots were blocked with 10% milk in TBST buffer, probed with 
antibodies diluted in 2.5% milk in TBST overnight at 4⁰C, and developed using 
ECL (Pierce; high sensitivity Millipore). Antibodies: E-cadherin (HECD-1, 1:2000, 
Invitrogen); EGFR (Ab-15, 1:2000, Neomarkers); ADAM10 (1:1000), ADAM15 
(1:1000) , tubulin (1:2000, Millipore).  
For immunoprecipitation (IP), 500ug of protein were pre-cleared with 100ul 
of a 50/50 mix of Sepharose A beads (Invitrogen) and 2.5% milk in TBST 
containing control IgG (mouse or rabbit IgG) for 30 minutes with end over end 
rotation. Lysates were then spun down for 3min at 8,000rpm and supernatants 
were transferred to new tubes containing 1ug of antibody and rotated end over 
end for 1hr at 4°C. Beads were then added and after another hour of rotation, 
and IPs were spun down for 3min at 8,000rpm and supernatants aspirated. 
Beads were washed three times and spun down. After final wash, supernatant 
was aspirated off and 35ul of beta-mercaptoethanol-containing loading buffer 
was added. After 5min at 100°C, IPs were again spun down and supernatants 
collected.  
 
In vitro cleavage assay 
 The in vitro cleavage assay has been previously described (43). Briefly, 
immunopurified ADAM10 or ADAM15 and E-cadherin were combined in 
Eppendorf tubes in PBS for 8hrs at 37°C. After incubation, 15ul of BME-
containing loading buffer were added and samples were boiled for 5min, spun 
down, and supernatants collected.  
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CD23 cleavage assay 
 Immunopurification of ADAM10 and 15 proceeded as described above. If 
appropriate, during the pre-clear step, lysates were pre-cleared with ADAM10 or 
ADAM15 in order to remove the reciprocal ADAM from the complex (Figure 5-1). 
Sepharose A beads containing immunopurified ADAM10 or ADAM15 were 
loaded into wells of a 96 well dish and topped with 100uM of CD23 peptide 
(PEPDAB013) provided by Dr. Marcia Moss (Biozyme). Plates were read after 2-
4 hours of incubation with a fluorescence Gemini Microplate Reader with an 
excitation wavelength of 485nm and emission 530nm.  Statistical analysis was 
performed by Graphpad Prism utilizing the Kruskal-Wallis test and Dunn’s 
multiple comparison test.  
 
Protein structure modeling 
 ADAM10 and 15 extracellular domains were modeled by Dr. Ron Rubin 
using PyMol (DeLano Scientific).  
 
97 
 
 
Figure 5-1: Modified immunoprecipitation protocol for CD23 peptide cleavage 
assay. 
 
 
Results 
ADAM15 over-expression in BPH-1 cells increases E-cadherin cleavage 
 Although the involvement of ADAM15 in E-cadherin cleavage in BPH-1 
cells appears limited (Chapter 3), over-expressing ADAM15 does result in 
increased sE-cad bound to EGFR (Figure 5-2). Unlike ADAM10, however, the 
addition of EGF does not aid in sE-cad generation, suggesting that EGF-
mediated E-cadherin cleavage is unique to ADAM10.  
 In ADAM15 cleavage of E-cadherin, we observed that cells containing a 
mutated EGF-like domain had less sE-cad in their conditioned media than non-
mutant ADAM15 over-expressing cell lines (Figure 5-3A). By comparing each cell 
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line’s ratio of untreated sE-cad to EGF treated sE-cad generation, we discovered 
that the parental and vector control cells treated with EGF had 1.2 and 1.4 fold 
more sE-cad than untreated counterparts. Over-expression of ADAM15 resulted 
in a 1:1 ratio of untreated to EGF treated sE-cad. Interestingly, the ADAM15 
EGF-like mutant had 1.3 fold more sE-cad in response to EGF and had regained 
its sensitivity to EGF, suggesting that ADAM15 activity had been abolished in 
these cells. Similarly, the amount of sE-cad bound to EGFR is also greatly 
reduced in response to the EGF-like domain mutant (Figure 5-3B). Since the 
EGF-like mutant still bound E-cadherin, we hypothesized that the EGF-like 
domain might aid in substrate recognition or alignment in ADAM15 cleavage. An 
in vitro cleavage assay revealed that in fact, the EGF like domain ADAM15 
mutant cannot cleave full length E-cadherin into sE-cad (Figure 5-3C). Previous 
work in our laboratory has demonstrated that ADAM15 cleavage of E-cadherin 
requires a functional metalloprotease domain (44), but this is the first observation 
of the EGF-like domain being required for proteolysis.  
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Figure 5-2: ADAM15 over-expression increases sE-cad bound to EGFR. BPH-1 
cells transfected with an ADAM15 construct (WT) generate more sE-cad bound to EGFR 
than vector transfected cells at 15min of treatment. In the ADAM15 over-expressing 
cells, 5nM EGF does not induce additional sE-cad generation. NT: no treatment. fE-cad: 
full length E-cadherin. sE-cad: soluble E-cadherin 
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Figure 5-3: E-cadherin cleavage is mediate by ADAM15’s EGF-like domain. A. 
Conditioned medium (CM) analysis of BPH-1 parental, vector, ADAM15 wild-type (WT), 
and ADAM15 ΔEGF mutant (ΔEGF) cell lines’ generation of sE-cad in response to no 
treatment (NT) or 5nM EGF for 24hrs. Western blot was quantitated using Image J and 
NT vs. EGF were compared within each cell line to determine the relative ratio of sE-cad 
shed into conditioned medium. B. Analysis of sE-cad bound to EGFR in response to 
5nM EGF treatment for 15min of BPH-1 vector, ADAM15 (WT), and ADAM15 ΔEGF 
(ΔEGF). C. 8hr in vitro cleavage assay of ADAM15 immunopurified by HA tag and 
reconstituted with E-cadherin.  
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ADAM10 and ADAM15 exist in complex 
 One of the observations during our studies was that the ADAM10 inhibitor 
INC (Incyte, 008765) could also inhibit ADAM15 activity in an in vitro cleavage 
assay (Figure 5-4A). Interestingly, an ADAM17 inhibitor does not inhibit ADAM15 
in the in vitro cleavage assay (Figure 5-4A), suggesting that maybe only 
ADAM10 specific drugs will target ADAM15. The ADAM10 inhibitor can also 
inhibit ADAM15 in the CD23 peptide cleavage assay (Figure 5-4B). These 
observations suggest two explanations: either the inhibitor was targeting both 
metalloproteases or ADAM10 and 15 exist in a complex and the activity of 
purified ADAM15 depends on bound ADAM10. Immunoprecipitation of ADAM15 
revealed bound ADAM10, suggesting that ADAM10 and ADAM15 do exist in a 
complex (Figure 5-5A), which was later reported by another group (38). Although 
cross-reactivity between ADAM antibodies and epitopes has yet to be ruled out, 
future studies could evaluate whether the ADAM10 antibody recognizes 
recombinant ADAM15 (and vice versa) in an ELISA.  
In order to determine which of the complex components was catalytically 
active, the CD23 peptide cleavage assay was modified to include ADAM10 and 
ADAM15 samples which had been pre-cleared with antibody against the opposite 
ADAM. For both ADAM10 and ADAM15, pre-clearing with the other ADAM 
reduced cleavage activity dramatically (Figure 5-5B). However, there was no 
difference between the levels of ADAM10 and ADAM15 pre-cleared with 
ADAM15 and ADAM10, respectively, suggesting that both metalloproteases act 
on the peptide.  Similarly,  ADAM10 and 15 immunopurified from AR positive 
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LNCaP and AR negative PC-3 cells exhibit an association between ADAM10 and 
15 (Figure 5-6A, B), suggesting the association occurs in BPH and cancer and is 
independent of AR status. There is evidence of  ADAM10 processing seen in 
prostate cancer patient samples (36) and others have published data implicating 
ADAM15 in this process (38). It is possible, therefore, that our cleavage data is 
recapitulating an increased association between ADAM10 and ADAM15 seen in 
patients.  
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Figure 5-4: ADAM10-specific inhibitors are effective against ADAM15. A. 8hr in vitro 
cleavage assay with immunopurified ADAM15 and E-cadherin from BPH-1 cells. 
ADAM15 cleavage reactions treated with no treatment (NT) or vehicle (DMSO) show 
higher levels of sE-cad generation than ADAM10 inhibitor (IN A10) treated reactions. B. 
CD23 cleavage assay. Immunopurified ADAM15 (A15) or ADAM10 (A10) was combined 
with CD23 peptide and ADAM10 inhibitor (IN, INCB08765). NT: no treatment. IN A10: 
ADAM10 inhibitor, INCB08765. IN A17: ADAM17 inhibitor INCB012881. IN: INCB08765. 
Peptide: CD23 peptide.  
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Figure 5-5: ADAM10 and ADAM15 exist in a functional complex in BPH-1 cells. A. 
Immunoprecipitation of ADAM15 reveals that ADAM10 is bound to ADAM15. B. CD23 
peptide cleavage assay. ADAM10 immunopurified from BPH-1 cells loses some catalytic 
activity when pre-cleared with an antibody against ADAM15 (pre A15). The converse is 
also true. *: p > 0.05  
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Figure 5-6: ADAM10 and ADAM15 exist in a functional complex in cancer cell 
lines. CD23 cleavage assay with ADAM10 and 15 immunopurified from (A) LNCaP and 
(B) PC-3 cells. LNCaP and PC-3 cells also have significant association between 
ADAM10 and 15. *: p > 0.05 
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Discussion  
 The focus of these preliminary studies has been to better characterize the 
roles of ADAM10 and ADAM15 in the prostate. The mutational analysis of 
ADAM15 in BPH-1 cells has been quite informative. First, we have made the 
observation that while ADAM15 over-expression can increase the amount of sE-
cad generated by BPH-1 cells, this process is not EGF dependent as observed 
under normal conditions (Chapter 3). Moreover, the process of E-cadherin 
cleavage by ADAM15 appears to be mediated by the EGF-like domain of 
ADAM15, which has not been previously reported. Disruption of this domain 
results in loss of sE-cad generation but not association with the full length E-
cadherin, suggesting that the EGF-like domain is responsible for substrate 
specificity.  
Interestingly, while the EGF-like domain appears critical for E-cadherin 
processing by ADAM15, ADAM10 does not contain an EGF-like domain (26) but 
processes E-cadherin successfully. This suggests a fundamental difference 
between ADAM10 and ADAM15 processing of substrates, which might be useful 
in drug design (Figure 5-7).  Because the Adam15 -/- knockout mouse is viable 
(56), while the Adam10 -/-mouse is embryonic lethal (55), our goal would be to 
target ADAM15 specifically to avoid systemic effects in patients. In these studies, 
the ADAM10-specific inhibitor INCB008765 showed activity against ADAM15, 
indicating that ADAM-specific drug design may be challenging.   
 Our studies have also suggested that ADAM10 and ADAM15 exist in a 
complex, which has been reported previously (38). Based on our CD23 peptide 
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cleavage data, it appears that both members of the complex are catalytically 
active, and that association occurs in BPH and cancer cells, independent of AR 
status. The specific consequences of this association for patients remain to be 
determined, although there is evidence suggesting that processing of ADAM10 
from the cell surface of cancer patient samples correlates with high grade 
prostate cancer (36) and our own studies have demonstrated high ADAM15 
expression in advanced disease (39). These preliminary studies have revealed a 
complex interaction between ADAM10 and ADAM15, which warrants further 
investigation.  
 
Figure 5-7: The extracellular domains of ADAM10 and 15.  Although ADAM10 and 15 
share substrates, ADAM15 contains an EGF-like domain (arrow) which it requires for E-
cadherin cleavage while ADAM10 does not. Modeling by Dr. Ron Rubin. 
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Chapter 6: Discussion 
 
Our interest in the disintegrin family was initiated by the observation that 
E-cadherin, which plays critical roles in epithelial cell maintenance, can be 
processed to sE-cad by ADAM15 during breast and prostate cancer progression 
(44, 170). Although ADAM15 is critical for E-cadherin processing in breast and 
prostate cancer, our preliminary studies suggested it does not play a significant 
role in normal prostate biology. The aims of this thesis project, therefore, were to 
identify and characterize the E-cadherin sheddase in untransformed prostate cell 
lines, generate prostate specific knockouts of said sheddase, and examine any 
interactions ADAM15 might have with this sheddase.  
Our initial studies of E-cadherin shedding in untransformed prostate 
epithelial cells (BPH-1 and PrEC) illustrated that expression of active ADAM15 
did not correlate with sE-cad levels. A related disintegrin, ADAM10, had been 
previously implicated in E-cadherin processing in keratinocytes (84), and 
expression of active ADAM10 correlated well with sE-cad generation. After pilot 
experiments with ADAM10 inhibitors, we determined that ADAM10 could indeed 
cleave E-cadherin to the 80kDa sE-cad fragment, and we set out to determine 
the role of ADAM10 and sE-cad in normal prostate biology and disease.  
109 
 
By blocking ADAM10 activity or reducing ADAM10 expression, we 
established that ADAM10 plays a role in signaling and proliferation of prostate 
cells. We also demonstrated that non-transformed prostate epithelial cells can be 
induced to generate sE-cad by adding EGF or amphiregulin and that this process 
is dependent upon ADAM10. Interestingly, if ADAM15 is over-expressed in these 
cells, generation of sE-cad increases, but it is no longer EGF-dependent. This 
suggests that while ADAM10 and ADAM15 may both play a role in E-cadherin 
cleavage and prostate pathologies, their stimulus varies. 
However it is generated, sE-cad can stimulate a variety of pro-survival 
effects (Chapter 2). While previous publications from our group have 
demonstrated that sE-cad can bind to HER2 and HER3 (44), this is the first 
report of the sE-cad bound to EGFR in a non-transformed prostate cell model. 
Our studies have also demonstrated that Fc-Ecad can induce phosphorylation of 
the receptor which results in downstream signaling. Moreover, these experiments 
have demonstrated that sE-cad may play a role in aberrant proliferation of 
prostate epithelial cells such as in BPH. This work and the literature supporting it 
suggests that the generation of sE-cad may contribute to the benign proliferative 
disorders by binding to EGFR and inducing downstream signaling. Additionally, 
the loss of E-cadherin at the cell membrane can also mediate epithelial to 
mesenchymal transition (EMT).  
EMT is characterized by the loss of differentiated epithelial phenotypes 
and the acquisition of motility and invasiveness and plays a critical role in tumor 
progression (96, 184). In prostate cancer, EMT has been implicated in models of 
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bone metastasis (97), and emerging evidence suggests EMT also may play a 
role in BPH (99). In BPH patient sections, areas of BPH stain strongly for EMT 
transcription factors Snail and Slug, suggesting that it is the accumulation of 
mesenchymal cells derived from epithelium which is driving the disease (99). 
These data suggest that the cleavage of E-cadherin induced by a potent EMT 
activator, such as EGF, may contribute to BPH progression via EMT, and 
presents ADAM10 as a possible therapeutic avenue for BPH intervention.  
In order to evaluate whether ADAM10 plays a role in normal prostate 
biology, we generated a prostate specific ADAM10 knockout mouse (ADAM10 
loxP/loxP  Pb-Cre). Preliminary evidence has been confounding. On the one hand, 
there is a very dramatic phenotype in the anterior prostate of 28 week old 
ADAM10 loxP/loxP  Pb-Cre mice. However, ADAM10 immunohistochemistry staining 
revealed continued expression of ADAM10 in the luminal cells, particularly 
intense in areas of hyperproliferation. We believe that this preliminary data 
indicates a role for ADAM10 in prostate tissue homeostasis because loss of 
ADAM10 appears to initiate a hyperproliferative response, which results in cell 
proliferation into the luminal space. This process appears to be coupled with 
basal cell differentiation since areas of strong ADAM10 expression persist in 
experimental prostates. Although these studies are preliminary, they do suggest 
a role for ADAM10 in mouse prostate biology. Based on the strong response to 
ADAM10 loss, further analysis with mouse models of BPH should be considered 
in order to validate or exclude ADAM10 as a target for BPH therapy. Additionally, 
further studies of adult ADAM10 knockout mice utilizing a tetracycline-induced 
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Cre could be highly informative for determining the role of ADAM10 in adult 
tissues.  
Beyond further characterization of the Adam10 loxP/loxP Pb-Cre mice, the 
established cell lines will also be further analyzed. The prostate epithelial cell 
lines established from an Adam10 loxP/loxP Pb-Cre mouse are viable and do not 
express ADAM10, and studies are currently underway to better characterize 
these cells in terms of epithelial (E)-cadherin cleavage. It would be interesting to 
determine whether our knockout cells are capable of regenerating prostatic 
tissue in a tissue recombination model. Based on the hyperproliferation observed 
in our animals in our preliminary studies, we hypothesize these cells would most 
likely not give rise to normal prostate.  
Whether or not the tissue recombination studies are undertaken, the 
ADAM10-/- prostate cell lines, along with previously generated Adam15-/- prostate 
epithelial cell lines will be tremendously useful in determining what roles 
ADAM10 and ADAM15 play in normal biology as well as in drug design. For 
example, highly specific ADAM15 inhibitors should have no effect on the 
shedding profile of ADAM15-/- cells. Additionally, the knockout cells will provide 
null backgrounds for ADAM10 and 15, which is particularly critical since these 
two disintegrins share substrates and interact with each other.   
Our studies have revealed that ADAM10 and ADAM15 exist in a complex, 
where it appears both members are catalytically active. ADAM15 has also been 
reported to aid in processing ADAM10 (38), and this could explain the 
observation that prostate cancer samples lose ADAM10 membranous expression 
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with increasing grade (36). Based on our CD23 peptide cleavage data, it would 
be interesting to repeat our observations in the context of DHT treatment. 
Because the processing of ADAM10 appears to be DHT dependent (36), we 
would hypothesize that treatment of AR positive LNCaP cells would result in 
increased association between ADAM10 and 15. For now, our observations hint 
at a regulated interaction between ADAM10 and ADAM15, which can become 
deregulated in prostate cancer.  
In order to explore the disregulation of ADAM15 in prostate cancer, we 
over-expressed ADAM15 in BPH-1 cells, which resulted in increased amounts of 
sE-cad, but this process became EGF independent. During these studies, we 
also observed that E-cadherin cleavage by ADAM15 appears to be mediated by 
the EGF-like domain of ADAM15, which has not been previously reported. 
Disruption of this domain results in loss of sE-cad generation but not association 
with the full length E-cadherin, suggesting that the EGF-like domain is 
responsible for substrate specificity. It is important to note that ADAM10 does not 
contain an EGF-like domain (26) but processes E-cadherin successfully, 
suggesting this might be a way to add specificity to ADAM15 targeting drugs. 
Currently there are no targeted therapies against ADAM15, but the ADAM10-
specific inhibitor INCB008765 shows activity against ADAM15, indicating that 
ADAM-specific drug design may be challenging.   
The studies included in this thesis have provided novel insight into the role 
of ADAM10 in human prostate epithelium. We have also included work that 
suggests important interactions between ADAM10 and ADAM15, which may play 
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a role in prostate cancer progression. The CD23 peptide cleavage assay and the 
Adam10 -/- cell lines will also be useful to future investigators in the laboratory for 
candidate drug screening. We believe the findings herein are novel, clinically 
relevant, and will provide a foundation for future studies of ADAM10 in the 
prostate gland.
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